+

WO2009126251A2 - Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator - Google Patents

Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator Download PDF

Info

Publication number
WO2009126251A2
WO2009126251A2 PCT/US2009/002163 US2009002163W WO2009126251A2 WO 2009126251 A2 WO2009126251 A2 WO 2009126251A2 US 2009002163 W US2009002163 W US 2009002163W WO 2009126251 A2 WO2009126251 A2 WO 2009126251A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
expression
cells
pluripotent
activity
Prior art date
Application number
PCT/US2009/002163
Other languages
French (fr)
Other versions
WO2009126251A3 (en
Inventor
Kenneth J. Eilertsen
Rachel A. Power
Jong S. Rim
Original Assignee
Nupotential, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nupotential, Inc. filed Critical Nupotential, Inc.
Priority to JP2011503981A priority Critical patent/JP2011516076A/en
Priority to EP09729724A priority patent/EP2274424A4/en
Priority to CN2009801207529A priority patent/CN102083981A/en
Priority to AU2009234424A priority patent/AU2009234424A1/en
Publication of WO2009126251A2 publication Critical patent/WO2009126251A2/en
Publication of WO2009126251A3 publication Critical patent/WO2009126251A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Definitions

  • Embodiments of the invention relate to the fields of cell biology, stem cells, cell differentiation, somatic cell nuclear transfer and cell-based therapeutics. More specifically, embodiments of the invention are related to methods, compositions and kits for reprogramming cells and cell-based therapeutics.
  • ES cells have tremendous plasticity, undifferentiated ES cells can form teratomas (benign tumors) containing a mixture of tissue types.
  • transplantation of ES cells from one source to another likely would require the administration of drugs to prevent rejection of the new cells.
  • Attempts have been made to identify new avenues for generating stem cells from tissues that are not of fetal origin.
  • chromosomal DNA is packaged into nucleosomes.
  • a nucleosome comprises a core and a linker.
  • the nucleosome core comprises an octamer of core histones (two each of H2A, H2B, H3 and H4) around which is wrapped approximately 150 base pairs of chromosomal DNA.
  • a linker DNA segment of approximately 50 base pairs is associated with linker histone H 1.
  • Nucleosomes are organized into a higher-order chromatin fiber and chromatin fibers are organized into chromosomes. See, for example, Wolffe “Chromatin: Structure and Function” 3.sup.rd Ed., Academic Press, San Diego, 1998.
  • Chromatin structure is not static, but is subject to modification by processes collectively known as chromatin remodeling.
  • Chromatin remodeling can serve, for example, to remove nucleosomes from a region of DNA; to move nucleosomes from one region of DNA to another; to change the spacing between nucleosomes; or to add nucleosomes to a region of DNA in the chromosome.
  • Chromatin remodeling can also result in changes in higher order structure, thereby influencing the balance between transcriptionally active chromatin (open chromatin or euchromatin) and transcriptionally inactive chromatin (closed chromatin or heterochromatin).
  • Chromosomal proteins are subject to numerous types of chemical modification.
  • HDAC histone deacetylase
  • HDACs are classified in at least four classes depending on sequence identity and domain organization: Class I: HDACl, HDAC2, HDAC3, HDAC8; Class II: HDAC4, HDAC5, HDAC6, HDAC7A, HDAC9, HDAClO; Class III: sirtuins in mammals (SIRTl , SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7); and Class IV: HDACl 1.
  • Class I HDACs are those that most closely resemble the yeast transcriptional regulator RPD3.
  • Class II HDACs are those that most closely resemble the yeast HDAl enzyme.
  • Histone acetylation and deacetylation has long been linked to transcriptional control.
  • the reversible acetylation of histones can result in chromatin remodeling and as such can act as a control mechanism for gene transcription.
  • hyperacetylation of histones facilitates gene expression, whereas histone deacetylation is correlated with transcriptional repression.
  • Histone acetyltransferases were shown to act as transcriptional coactivators, whereas deacetylases were found to belong to transcriptional repression pathways.
  • the invention relates to methods, compositions and kits for reprogramming a cell.
  • Embodiments of the invention relate to methods comprising inducing the expression of a pluripotent or multipotent gene.
  • the invention further relates to producing a reprogrammed cell.
  • the invention relates to a method comprising inhibiting the activity, expression or activity and expression of at least one HDAC by use of an HDAC inhibitor.
  • the invention relates to a method comprising altering the activity, expression or activity and expression of at least one HDAC by use of an HDAC modulator. The method further comprises inducing the expression of at least one pluripotent or multipotent gene, and reprogramming the cell.
  • Embodiments of the invention also relate to methods for reprogramming a cell comprising contacting a cell, a population of cells, a cell culture, a subset of cells from a cell culture, a homogeneous cell culture or a heterogeneous cell culture with an HDAC modulator, inducing the expression of at least one pluripotent or multipotent gene, and reprogramming the cell.
  • the method further comprises re-differentiating the reprogrammed cell.
  • the invention relates to the use of an agent to inhibit the expression, activity or expression and activity of an HDAC.
  • the agent can be any molecule or compound that can inhibit the expression, activity, or expression and activity of an HDAC including but not limited to an HDAC inhibitor, a small molecule, a nucleic acid sequence, a DNA sequence, an RNA sequence, a shRNA sequence, and RNA interference.
  • the invention relates to the use of an agent to induce the activity, expression, or activity and expression of a protein that inhibits the activity of an HDAC.
  • the agent can be any molecule or compound that can induce the expression, activity, or expression and activity of a protein that inhibits an HDAC including but not limited to a small molecule, a nucleic acid sequence, a DNA sequence, an RNA sequence, a shRNA sequence, and RNA interference
  • An HDAC inhibitor can be used to inhibit the activity of an HDAC and includes but is not limited to TSA, sodium butyrate, valproic acid, vorinostat, LBH- 589, apicidin, TPX-HA analogue, CI-994, MS-275, MGCD0103, and derivatives or analogues of the above-mentioned.
  • At least one HDAC inhibitor can inhibit at least one HDAC.
  • more than one HDAC inhibitor can inhibit at least one HDAC.
  • An HDAC inhibitor can be directed toward an HDAC in class I, class II, class III, class IV, or an unknown or unclassified HDAC.
  • An HDAC inhibitor can be directed toward more than one class of HDACs or all classes of HDACs. Combinations of HDAC inhibitors can inhibit more than one HDAC, and can be used simultaneously or sequentially.
  • the invention in another embodiment, relates to a method for reprogramming a cell comprising: exposing a population of cells to an agent that inhibits activity, expression, or activity and expression of a histone deacetylase; inducing expression of a pluripotent or multipotent gene; selecting a cell that express a cell surface marker indicative of a pluripotent or multipotent cell, and expanding said selected cell to produce a population of cells, wherein differentiation potential has been restored to said cell.
  • the invention relates to a method for reprogramming a cell comprising: exposing a cell to a first agent that inhibits that activity, expression or expression and activity of a HDAC; exposing said cell to a second agent that inhibits the activity, expression or expression and activity of a second regulatory protein, wherein said second regulatory protein has a distinct function from the HDAC, inducing expression of a pluripotent or multipotent gene, and selecting a cell, wherein differentiation potential has been restored to said cell.
  • the cell or population of cells may be exposed to the first and second agent simultaneously or sequentially.
  • the invention relates to a method comprises exposing a cell with a first phenotype to an agent that inhibits the activity, expression or activity and expression of at least one HDAC; comparing the first phenotype of the cell to a phenotype obtained after exposing the cell to said agent, and selecting the cell that has been reprogrammed.
  • the method comprises comparing the genotype of a cell prior to exposing the cell to said agent to a genotype of the cell obtained after exposing said cell to said agent.
  • the method comprises comparing the phenotype and genotype of a cell prior to exposing the cell to an agent that inhibits the activity, expression or activity and expression of at least one HDAC to the phenotype and genotype of the cell after exposing the cell to said agent.
  • the method comprises culturing or expanding the selected cell to a population of cells.
  • the method comprises isolating a cell using an antibody that binds to a protein coded for by a pluripotent or multipotent gene or an antibody that binds to a multipotent marker or a pluripotent marker, including but not limited to SSEA3, SSEA4, Tra-1-60, and Tra-1- 81.
  • Cells may also be isolated using any method efficient for isolating cells including but not limited to a fluorescent cell activated sorter, immunohistochemistry, and ELISA.
  • the method comprises selecting a cell that has a less differentiated state than the original cell.
  • the invention further comprises comparing chromatin structure of a pluripotent or multipotent gene prior to exposure to said agent to the chromatin structure obtained after exposure to said agent.
  • the invention relates to a method for reprogramming a cell comprising: exposing a cell with a first transcriptional pattern to an agent that inhibits the activity, expression or activity and expression of a HDAC; inducing expression of a pluripotent or multipotent gene; comparing the first transcriptional pattern of the cell to a transcriptional pattern obtained after exposure to said agent; and selecting a cell, wherein differentiation potential has been restored to said cell.
  • selecting a cell comprises identifying a cell with a transcriptional pattern that is at least 5-10%, 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, 90-94%, 95%, or 95-99% similar to an analyzed transcriptional pattern of an embryonic stem cell.
  • the entire transcriptional pattern of an embryonic stem cell need not be compared, although it may. Instead, a subset of embryonic genes may be compared including but not limited to 1-5, 5-10, 10-25, 25-50, 50-100, 100-200, 200-500, 500-1,000, 1,000-2,000, 2,000-2,500, 2,500- 5,000, 5,000-10,000 and greater than 10,000 genes.
  • the transcriptional patterns may be compared in a binary fashion, i.e., the comparison is made to determine if the gene is transcribed or not. In another embodiment, the rate and/or extent of transcription for each gene or a subset of genes may be compared. Transcriptional patterns can be determined using any methods known in the art including but not limited to RT-PCR, quantitative PCR, a microarray, southern blot and hybridization. [0025] Embodiments of the invention also include methods comprising treating a variety of diseases using a reprogrammed cell produced according to the methods disclosed herein. In yet another embodiment, the invention also relates to therapeutic uses for reprogrammed cells and reprogrammed cells that have been re-differentiated.
  • Embodiments of the invention also relate to a reprogrammed cell produced by the methods of the invention.
  • the reprogrammed cell can be re-differentiated into a single lineage or more than one lineage.
  • the reprogrammed cell can be multipotent or pluripotent.
  • the invention relates to an enriched population of reprogrammed cells produced according to a method comprising the steps of: exposing a population of cells to an agent that inhibits activity, expression of activity and expression of a histone deacetylase; inducing expression of a pluripotent or multipotent gene; selecting a cell that express a cell surface marker indicative of a pluripotent or multipotent cell, and expanding said selected cell to produce a population of cells, wherein differentiation potential has been restored to said cell [0028]
  • the reprogrammed cell expresses a cell surface marker indicative of a pluripotent cell selected from the group consisting of: SSEA3, SSEA4, Tra-1-60, and Tra-1-81.
  • the reprogrammed cell expresses a pluripotent gene including but not limited to Oct-4, Sox-2 and Nanog.
  • the reprogrammed cells account for at least 5-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, 90-95%, 96-98%; or at least 99% of the enriched population of cells [0029]
  • kits for preparing the methods and compositions of the invention can be used for, among other things, reprogramming a cell and generating ES-like and stem cell-like cells.
  • FIG. 1 is a bar graph reporting the up-regulation of Oct-4 in primary human lung cells treated with valproic acid (VPA).
  • FIG. 2 is a bar graph reporting the up-regulation of several genes, which confer stem-cell like characteristics, in primary human lung cells treated with an
  • VPA HDAC inhibitor
  • FIG. 3 is an illustration reporting the demethylation of two cytosines in the first exon of Oct-4 in cells treated with VPA.
  • FIG. 4A is a graph reporting the effects on the gene Nanog as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in adult human dermal fibroblasts.
  • FIG. 4B is a graph reporting the effects on the gene
  • FIG. 4C is a graph reporting the effects on the gene Nanog as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in fetal human dermal fibroblasts.
  • FIG. 5A is a graph reporting the effects on the gene Oct-4 as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in adult human dermal fibroblasts.
  • FIG. 5B is a graph reporting the effects on the gene
  • FIG. 5C is a graph reporting the effects on the gene Oct-4 as measured by fold-change in mRNA expression during HDAC7 or HDAC 11 shRNA interference in fetal human dermal fibroblasts.
  • FIG. 6 is a graph reporting the effects on the gene Sox-2 as measured by fold-change in mRNA expression during HDAC7 or HDAC 1 1 shRNA interference in fetal human dermal fibroblasts.
  • FIG 7 is a graph reporting the effects on various HDAC and SIRT genes as measured by mRNA expression during HDAC7 shRNA interference in human dermal fibroblasts.
  • FIG. 8 is a graph reporting the effects on the gene Nanog as measured by fold-change in mRNA expression during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf)-
  • FIG. 9 is a graph reporting the effects on the gene Oct-4 as measured by fold-change in mRNA expression during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf).
  • HDFa adult human dermal fibroblasts
  • HDFn neonatal human dermal fibroblasts
  • HDFf fetal human dermal fibroblasts
  • FIG. 10 is a graph reporting the effects on the gene Sox-2 as measured by fold-change in mRNA expression during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf).
  • HDFa adult human dermal fibroblasts
  • HDFn neonatal human dermal fibroblasts
  • HDFf fetal human dermal fibroblasts
  • FIG. 1 1 is a graph reporting the effects on various HDAC genes and SIRT genes as measured by fold change in mRNA expression during dual HDAC7 and
  • HDACl 1 shRNA interference in adult human dermal fibroblasts HDACl 1 shRNA interference in adult human dermal fibroblasts.
  • FIG. 12 is a graph reporting the effects on various HDAC genes and SIRT genes as measured by fold change in mRNA expression during dual HDAC7 and
  • HDACl 1 shRNA interference in fetal human dermal fibroblasts.
  • FIG. 13 is a graph reporting the effects on various HDAC genes and SIRT genes as measured by fold change in mRNA expression during dual HDAC7 and
  • HDACl 1 shRNA interference in neonatal human dermal fibroblasts HDACl 1 shRNA interference in neonatal human dermal fibroblasts.
  • FIG. 14A is a graph reporting the effect of HDAC7a shRNA on the expression of HDAC7a and HDAC 11 in adult human dermal fibroblasts. Data for cells grown both in the absence and presence of puromycin are reported.
  • FIG. 14B is a graph reporting the effect of HDAC7a shRNA on the expression of HDAC7a and HDAC 11 in neonatal human dermal fibroblasts. Data for cells grown both in the absence and presence of puromycin are reported.
  • FIG. 14C is a graph reporting the effect of HDAC7a shRNA on the expression of HDAC7a and HDACl 1 in fetal human dermal fibroblasts.
  • FIG. 15 A is a photograph of fetal human dermal fibroblasts.
  • FIG. 15B is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 15C is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 15D is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 15E is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 15F is a photograph of fetal human dermal fibroblasts infected with
  • HDACl 1 and HDAC7 shRNA are HDACl 1 and HDAC7 shRNA.
  • FIG. 15G is a photograph of human embryonic stem cells.
  • FIG. 16A is a photograph of fetal human dermal fibroblasts.
  • FIG. 16B is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 16C is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 16D is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 16E is a photograph of fetal human dermal fibroblasts infected with
  • FIG. 16F is a photograph of fetal human dermal fibroblasts infected with
  • HDACl 1 and HDAC7 shRNA are HDACl 1 and HDAC7 shRNA.
  • FIG. 16G is a photograph of human embryonic stem cells.
  • one unit is considered to be 0.0001, 0.001, 0.01 or
  • Cell or “cells,” unless specifically limited to the contrary, includes any somatic cell, embryonic stem (ES) cell, adult stem cell, an organ specific stem cell, nuclear transfer (NT) units, and stem-like cells.
  • the cell or cells can be obtained from any organ or tissue.
  • the cell or cells can be human or other animal.
  • a cell can be mouse, guinea pig, rat, cattle, horses, pigs, sheep, goats, etc.
  • a cell also can be from non-human primates.
  • Culture Medium or "Growth Medium” means a suitable medium capable of supporting growth of cells.
  • Epigenetics means the state of DNA with respect to heritable changes in function without a change in the nucleotide sequence. Epigenetic changes can be caused by modification of the DNA, such as by methylation and demethylation, without any change in the nucleotide sequence of the DNA.
  • Histone means a class of protein molecules found in chromosomes responsible for compacting DNA enough so that it will fit within a nucleus.
  • Histone deacetylase inhibitor and “inhibitor of histone deacetylase” mean a compound that is capable of interacting with a histone deacetylase and inhibiting its enzymatic activity.
  • “Inhibiting histone deacetylase activity” means reducing the ability of a histone deacetylase to remove an acetyl group from a suitable substrate, such as a histone, or other protein. In some embodiments, such reduction of histone deacetylase activity is at least about 10-25%, in other embodiments at least about 50%, in other embodiments at least about 75%, and still in other embodiments at least about 90%. In still yet other embodiments, histone deacetylase activity is reduced by at least 95% and in other embodiments by at least 99%.
  • knock down means to suppress the expression of a gene in a gene-specific fashion.
  • a cell that has one or more genes “knocked down,” is referred to as a knock-down organism or simply a “knock-down.”
  • Pluripotent means capable of differentiating into cell types of the 3 germ layers or primary tissue types.
  • Pluripotent gene means a gene that contributes to a cell being pluripotent.
  • Pluripotent cell cultures are said to be “substantially undifferentiated” when that display morphology that clearly distinguishes them from differentiated cells of embryo or adult origin. Pluripotent cells typically have high nuclear/cytoplasmic ratios, prominent nucleoli, and compact colony formation with poorly discernable cell junctions, and are easily recognized by those skilled in the art. It is recognized that colonies of undifferentiated cells can be surrounded by neighboring cells that are differentiated. Nevertheless, the substantially undifferentiated colony will persist when cultured under appropriate conditions, and undifferentiated cells constitute a prominent proportion of cells growing upon splitting of the cultured cells.
  • Useful cell populations described in this disclosure contain any proportion of substantially undifferentiated pluripotent cells having these criteria.
  • Substantially undifferentiated cell cultures may contain at least about 20%, 40%, 60%, or even 80% undifferentiated pluripotent cells (in percentage of total cells in the population).
  • "Regulatory protein” means any protein that regulates a biological process, including regulation in a positive and negative direction. The regulatory protein can have direct or indirect effects on the biological process, and can either exert affects directly or through participation in a complex.
  • Reprogramming means removing epigenetic marks in the nucleus, followed by establishment of a different set of epigenetic marks.
  • different cells and tissues acquire different programs of gene expression. These distinct gene expression patterns appear to be substantially regulated by epigenetic modifications such as DNA methylation, histone modifications and other chromatin binding proteins.
  • epigenetic modifications such as DNA methylation, histone modifications and other chromatin binding proteins.
  • each cell type within a multicellular organism has a unique epigenetic signature that is conventionally thought to become “fixed” and immutable once the cells differentiate or exit the cell cycle.
  • some cells undergo major epigenetic "reprogramming" during normal development or certain disease situations.
  • Totipotent means capable of developing into a complete embryo or organ.
  • Embodiments of the invention relate to methods comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In another embodiment, the invention relates to methods comprising inducing the expression of at least one gene that contributes to a cell being multipotent. In some embodiments, the methods comprise inducing expression of at least one gene that contributes to a cell being pluripotent or multipotent and producing reprogrammed cells that are capable of directed differentiation into at least one lineage. [0076] Embodiments of the invention also relate to methods comprising modifying chromatin structure, and reprogramming a cell to be pluripotent or multipotent. In yet another embodiment, modifying chromatin structure comprises inhibiting the activity of an HDAC.
  • the method comprises inhibiting the activity of an HDAC, and inducing expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the activity of an HDAC and producing a reprogrammed cell. [0078] In still another embodiment, the invention relates to a method for reprogramming a cell comprising: exposing a cell to an agent that inhibits the activity, expression or activity and expression of an HDAC, inducing expression of a pluripotent or multipotent gene; and selecting a cell, wherein differentiation potential has been restored to said cell.
  • the pluripotent or multipotent gene may be induced by any fold increase in expression including but not limited to 0.25-0.5, 0.5-1, 1.0-2.5, 2.5-5, 5-10, 10-15, 15-20, 20-40, 40-50, 50-100, 100-200, 200-500, and greater than 500.
  • the method comprises plating differentiated cells, exposing said differentiated cell to an agent that inhibits the activity, expression, or activity and expression of an HDAC, culturing said cells, and identifying a cell that has been reprogrammed.
  • the invention in another embodiment, relates to a method for reprogramming a cell comprising exposing a cell to an agent that induces the expression, activity, or expression and activity a regulatory protein that inhibits the activity of an HDAC, inducing expression of a pluripotent or multipotent gene; and selecting a cell, wherein differentiation potential has been restored to said cell.
  • the activity or expression of a regulatory protein can be increased by any amount including but not limited to 1-5%, 5-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, 90-95%, and 95-99%, 99-200%, 200-300%, 300-400%, 400-500% and greater than 500%.
  • the method further comprises selecting a cell using an antibody directed to a protein or a fragment of a protein coded for by a pluripotent or multipotent gene or a pluripotent surface marker.
  • an antibody directed to a protein or a fragment of a protein coded for by a pluripotent or multipotent gene or a pluripotent surface marker.
  • Any type of antibody can be used including but not limited to a monoclonal, a polyclonal, a fragment of an antibody, a peptide mimetic, an antibody to the active region, and an antibody to the conserved region of a protein
  • the method further comprises selecting a cell using a reporter driven by a pluripotent or mulitpotent gene or a pluripotent or mulitpotent surface marker.
  • a reporter driven by a pluripotent or mulitpotent gene or a pluripotent or mulitpotent surface marker.
  • Any type of reporter can be used including but not limited to a fluorescent protein, green fluorescent protein, cyan fluorescent protein (CFP), a yellow fluorescent protein (YFP), bacterial luciferase, jellyfish aequorin, enhanced green fluorescent protein, chloramphenicol acetyltransferase (CAT), dsRED, ⁇ - galactosidase, and alkaline phosphatase.
  • the method further comprises selecting a cell using resistance as a selectable marker including but not limited to resistance to an antibiotic, a fungicide, puromycin, hygromycin, dihydrofolate reductase, thymidine kinase, neomycin resistance (neo), G418 resistance, mycophenolic acid resistance (gpt), zeocin resistance protein and streptomycin.
  • resistance including but not limited to resistance to an antibiotic, a fungicide, puromycin, hygromycin, dihydrofolate reductase, thymidine kinase, neomycin resistance (neo), G418 resistance, mycophenolic acid resistance (gpt), zeocin resistance protein and streptomycin.
  • the method further comprises comparing the chromatin structure of a pluripotent or multipotent gene of a cell, prior to exposing said cell to an agent that inhibits the activity, expression or activity and expression of an HDAC, to the chromatin structure of a pluripotent or multipotent gene obtained after treatment with said agent.
  • Any aspect of chromatin structure can be compared including but not limited to euchromatin, heterochromatin, histone acetylation, histone methylation, the presence and absence of histone or histone components, the location of histones, the arrangement of histones, and the presence or absence of regulatory proteins associated with chromatin.
  • the method comprises inhibiting the activity of at least one HDAC, demethylating at least one cytosine in a CpG dinucleotide, and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent.
  • the method comprises contacting a cell with an HDAC inhibitor; inhibiting the activity of an HDAC; and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent.
  • the method further comprises producing a reprogrammed cell.
  • the reprogrammed cell can be pluripotent or multipotent.
  • an HDAC inhibitor of the methods, compositions and kits of the invention may interact with any HDAC.
  • an HDAC inhibitor of the invention may interact with an HDAC from one of the four known classes of HDACs.
  • An HDAC inhibitor of the invention may interact with an HDAC of class I, class II, class III, or class IV.
  • An HDAC inhibitor may interact with one specific class of HDACs, all classes of HDACS, or with multiple classes of HDACs including but not limited class I and class II; class I and class III; class I and class IV; class II and class III; class II and class IV; class HI and class IV; class I, II and III; class II, III and IV; and class I, II, III and IV.
  • An HDAC inhibitor may also interact with HDACs that do not fall into one of the known classes.
  • An HDAC inhibitor may have an irreversible mechanism of action or a reversible mechanism of action.
  • An HDAC inhibitor can have any binding affinity including but not limited to millimolar (mM), micromolar ( ⁇ M), nanomolar (nM), picomolar (pM), and fentamolar (fM).
  • mM millimolar
  • ⁇ M micromolar
  • nM nanomolar
  • pM picomolar
  • fM fentamolar
  • such inhibition is specific, i.e., the histone deacetylase inhibitor, reduces the ability of a histone deacetylase to remove an acetyl group from a histone at a concentration that is lower than the concentration of the inhibitor that is required to produce another, unrelated biological effect.
  • the concentration of the inhibitor required for histone deacetylase inhibitory activity is at least 2-fold lower, more preferably at least 5 -fold lower, even more preferably at least 10-fold lower, and most preferably at least 20-fold lower than the concentration required to produce an unrelated biological effect.
  • the HDAC inhibitor may act by binding to the zinc containing catalytic domain of the HDACs.
  • HDAC inhibitors with this mechanism of action fall into several groupings: (i) hyroxamic acids, such as Trichostatin A; (ii) cyclic tetrapeptides; (iii) benzamides; (iv) electrophilic ketones; and (v) the aliphatic acid group of compounds such as phenylbutyrate and valproic acid.
  • the HDAC inhibitor can be directed toward the sirtuin Class III HDACs, which are NAD+ dependent and include but are not limited to nicotinamide, derivatives of NAD, dihydrocoumarin, naphthopyranone, and 2- hydroxynaphaldehydes .
  • the HDAC inhibitor can alter the degree of acetylation of nonhistone effector molecules and thereby increase the transcription of genes.
  • HDAC inhibitors of the methods, compositions, and kits of the invention should not be considered to act solely as enzyme inhibitors of HDACs.
  • a large variety of nonhistone transcription factors and transcriptional co-regulators are known to be modified by acetylation, including but not limited to ACTR, cMyb, p300, CBP, E2F1, EKLF, FEN 1, GATA, HNF-4, HSP90, Ku70, NFKB, PCNA, p53, RB, Runx, SFl Sp3, STAT, TFIIE, TCF, and YYl.
  • the activity of any transcription factor or protein involved in activating transcription could be increased with the methods of the invention.
  • Table I provides a representative list of compounds that can function as an HDAC inhibitor.
  • the reference to "Isotype" in Table I is meant to merely provide insight as to whether the compound has a preference for a particular class of HDAC.
  • Listing a specific isotype or class of HDAC should not be construed to mean that the compound only has affinity for that isotype or class.
  • HDAC inhibitors of the present invention include derivatives and analogues of any HDAC inhibitor herein mentioned.
  • Butyric acid, or butyrate was the first HDAC inhibitor to be identified. However, in millimolar concentrations, butyrate may not be specific for HDAC, it also may inhibit phosphorylation and methylation of nucleoproteins as well as DNA methylation.
  • TPX trichostatin A
  • TPX trapoxin
  • TSA trichostatin A
  • TPX trapoxin
  • VPA Valproic acid
  • VPA is a known drug with multiple biological activities that depend on different molecular mechanisms of action.
  • VPA is an antiepileptic drug.
  • VPA is teratogenic.
  • VPA When used as antiepileptic drug during pregnancy, VPA may induce birth defects (neural tube closure defects and other malformations) in a few percent of born children. In mice, VPA is teratogenic in the majority of mouse embryos when properly dosed. VPA activates a nuclear hormone receptor (PPAR-delta.).
  • Table I A representative list of compounds that can function as an HDAC inhibitor.
  • HDAC inhibitors also are available from Sigma Aldrich (St. Louis, MO) including but not limited to APHA Compound; Apicidin; Depudecin; Scriptaid; Sirtinol; and Trichostatin A.
  • HDAC inhibitors are available from Vinci-Biochem (Italy) including but not limited to 5-Aza-2'- deoxycytidine; CAY10398; CAY10433; ⁇ -Chloro ⁇ SA ⁇ -tetrahydro-lH-carbazole-l- carboxamide; HC Toxin; ITSAl ; M344; MC 1293; MS-275; Oxamflatin; PXDlOl ; SAHA; Scriptaid; Sirtinol; Splitomicin.
  • Dexamethasone may also be used in combination with any HDAC inhibitor.
  • a composition comprising dexamethasone and to 5-Aza-2'-deoxycytidine can be used.
  • HDAC inhibitors can be used, including but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1-15, 16-20, and 21-25 HDAC inhibitors.
  • One or more than one family of inhibitory proteins may be inhibited.
  • One or more than one mechanism of inhibition may be used including but not limited to small molecule inhibitors, HDAC inhibitors, shRNA, RNA interference, and small interfering RNA.
  • the invention relates to a method of reprogramming a cell comprising inhibiting two or more inhibitory proteins that function in a compensatory pathway.
  • the invention relate to a method of reprogramming a cell comprising inhibiting two or more proteins that function in a redundant pathway.
  • the invention relates to a method of reprogramming a cell comprising inhibiting one or HDAC proteins, and inhibiting one or more proteins that functions to compensate for the inhibited HDAC.
  • the inhibition of one inhibitory protein e.g, an HDAC, can lead to an increase in the expression of one or more other inhibitory proteins.
  • Inhibiting the expression of the redundant, compensatory, or the redundant and compensatory proteins can be accomplished using any suitable method including but not limited to shRNA, RNA interference, HDAC inhibitors, and small molecule inhibitors.
  • the invention relates to methods for reprogramming a cell comprising inhibiting the expression, activity, or the expression and activity of an inhibitory protein, wherein the inhibition of said inhibitory protein does not cause an increase in the expression, activity, or expression and activity of other inhibitory proteins.
  • the invention relates to a method for reprogramming a cell comprising inhibiting the expression, activity, or the expression and activity of an inhibitory protein, wherein the inhibition of said inhibitory protein does not cause an increase in the expression, activity, or expression and activity of a compensatory protein.
  • the invention relates to a method for reprogramming a cell comprising inhibiting the expression, activity, or the expression and activity of an inhibitory protein, wherein the inhibition of said inhibitory protein does not cause an increase in the expression, activity, or expression and activity of a redundant protein.
  • the invention relates to a method for reprogramming a cell comprising: exposing a cell to an agent that inhibits that activity, expression or expression and activity of more than one regulatory protein.
  • the regulatory protein can be of the same family or a distinct protein family member.
  • the invention relates to a method for reprogramming a cell comprising: exposing a cell to an agent that inhibits that activity, expression or expression and activity of a first regulatory protein; exposing said cell to a second agent that inhibits the activity, expression or expression and activity of a second regulatory protein, wherein said second regulatory protein has a distinct function from the first regulatory protein.
  • the first and second regulatory proteins can be any protein involved in regulating or altering expression of proteins including but not limited to a histone deacetylase, a histone acetyltransferase, a lysine methyltransferase, a histone methyltransferase, a Trichostatin A, a histone demethylase, a lysine demethylase, a sirtuin, and a sirtuin activator, nuclear receptors, orphan nuclear receptors, Esrr ⁇ and Esrr ⁇ .
  • a reprogrammed cell produced by the methods of the invention may be pluripotent or multipotent.
  • a reprogrammed cell produced by the methods of the invention can have a variety of different properties including embryonic stem cell like properties.
  • a reprogrammed cell may be capable of proliferating for at least 10, 15, 20, 30, or more passages in an undifferentiated state.
  • a reprogrammed cell can proliferate for more than a year without differentiating.
  • Reprogrammed cells can also maintain a normal karyotype while proliferating and/or differentiating.
  • Some reprogrammed cells also can be cells capable of indefinite proliferation in vitro in an undifferentiated state.
  • Some reprogrammed cells also can maintain a normal karyotype through prolonged culture. Some reprogrammed cells can maintain the potential to differentiate to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture. Some reprogrammed cells can form any cell type in the organism. Some reprogrammed cells can form embryoid bodies under certain conditions, such as growth on media that do not maintain undifferentiated growth. Some reprogrammed cells can form chimeras through fusion with a blastocyst, for example.
  • Reprogrammed cells can be defined by a variety of markers. For example, some reprogrammed cells express alkaline phosphatase. Some reprogrammed cells express SSEA-I, SSEA-3, SSEA-4, TRA- 1-60, and/or TRA- 1-81. Some reprogrammed cells express Oct 4, Sox2, and Nanog. It is understood that some reprogrammed cells will express these at the mRNA level, and still others will also express them at the protein level, on for example, the cell surface or within the cell. [00105] A reprogrammed cell can have any combination of any reprogrammed cell property or category or categories and properties discussed herein.
  • a reprogrammed cell can express alkaline phosphatase, not express SSEA-I, proliferate for at least 20 passages, and be capable of differentiating into any cell type.
  • Another reprogrammed cell for example, can express SSEA-I on the cell surface, and be capable of forming endoderm, mesoderm, and ectoderm tissue and be cultured for over a year without differentiation.
  • a reprogrammed cell can be alkaline phosphatase (AP) positive, SSEA-I positive, and SSEA-4 negative.
  • a reprogrammed cell also can be Nanog positive, Sox2 positive, and Oct-4 positive.
  • a reprogrammed cell also can be Tell positive, and Tbx3 positive.
  • a reprogrammed cell can also be Cripto positive, Stellar positive and Dazl positive.
  • a reprogrammed cell can express cell surface antigens that bind with antibodies having the binding specificity of monoclonal antibodies TRA- 1-60 (ATCC HB-4783) and TRA- 1-81 (ATCC HB-4784). Further, as disclosed herein, a reprogrammed cell can be maintained without a feeder layer for at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 passages or for over a year.
  • a reprogrammed cell may have the potential to differentiate into a wide variety of cell types of different lineages including fibroblasts, osteoblasts, chondrocytes, adipocytes, skeletal muscle, endothelium, stroma, smooth muscle, cardiac muscle, neural cells, hemiopoetic cells, pancreatic islet, or virtually any cell of the body.
  • a reprogrammed cell may have the potential to differentiate into all cell lineages.
  • a reprogrammed cell may have the potential to differentiate into any number of lineages including 1, 2, 3, 4, 5, 6-10, 1 1-20, 21-30, and greater than 30 lineages.
  • Any gene that contributes to a cell being pluripotent or multipotent may be induced by the methods of the invention including but not limited to glycine N- methyltransferase (Gnmt), Octamer-4 (Oct4), Nanog, SRY (sex determining region Y)-box 2 (also known as Sox2), Myc, REX-I (also known as Zfp-42), Integrin ⁇ -6, Rox-1, LIF-R, TDGFl (CRIPTO), Fragilis, SALL4 (sal-like 4), GABRB3, LEFTB, NR6A1, PODXL, PTEN, Leukocyte cell derived chemotaxin 1 (LECTl), BUBl, and Kr ⁇ ppel-like factors (KIf) such as Klf4 and Klf5.
  • Gnmt glycine N- methyltransferase
  • Octamer-4 Octamer-4
  • Nanog Nanog
  • SRY se determining region Y-
  • Embodiments of the invention also relate to methods for reprogramming a cell comprising modifying chromatin structure of a gene, and inducing the expression of said gene.
  • the method comprises modifying the chromatin structure of a pluripotent or multipotent gene.
  • the method further comprises modifying the chromatin structure by modifying a histone. Modifying a histone includes but is not limited to acetylation; methylation; demethylation; phosphorylation; ubiquitination; sumoylation; ADP-ribosylation; deimination and proline isomerization.
  • Embodiments of the invention also include methods for treating a variety of diseases using a reprogrammed cell produced according to the methods disclosed herein.
  • the skilled artisan would appreciate, based upon the disclosure provided herein, the value and potential of regenerative medicine in treating a wide plethora of diseases including, but not limited to, heart disease, diabetes, skin diseases and skin grafts, spinal cord injuries, Parkinson's disease, multiple sclerosis, Alzheimer's disease, and the like.
  • the invention encompasses methods for administering reprogrammed cells to an animal, including humans, in order to treat diseases where the introduction of new, undamaged cells will provide some form of therapeutic relief.
  • reprogrammed cells can be administered to an animal as a re-differentiated cell, for example, a neuron, and will be useful in replacing diseased or damaged neurons in the animal. Additionally, a reprogrammed cell can be administered to the animal and upon receiving signals and cues from the surrounding milieu, can re-differentiate into a desired cell type dictated by the neighboring cellular milieu. Alternatively, the cell can be re-differentiated in vitro and the differentiated cell can be administered to a mammal in need there of. [00114] The reprogrammed cells can be prepared for grafting to ensure long term survival in the in vivo environment.
  • cells can be propagated in a suitable culture medium, such as progenitor medium, for growth and maintenance of the cells and allowed to grow to confluence.
  • the cells are loosened from the culture substrate using, for example, a buffered solution such as phosphate buffered saline (PBS) containing 0.05% trypsin supplemented with 1 mg/ml of glucose; 0.1 mg/ml of MgCl.sub.2, 0.1 mg/ml CaCl.sub.2 (complete PBS) plus 5% serum to inactivate trypsin.
  • PBS phosphate buffered saline
  • the cells can be washed with PBS using centrifugation and are then resuspended in the complete PBS without trypsin and at a selected density for injection.
  • Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampoules or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
  • the invention also encompasses grafting reprogrammed cells in combination with other therapeutic procedures to treat disease or trauma in the body, including the CNS, PNS, skin, liver, kidney, heart, pancreas, and the like.
  • reprogrammed cells of the invention may be co-grafted with other cells, both genetically modified and non-genetically modified cells which exert beneficial effects on the patient, such as chromaffin cells from the adrenal gland, fetal brain tissue cells and placental cells. Therefore the methods disclosed herein can be combined with other therapeutic procedures as would be understood by one skilled in the art once armed with the teachings provided herein.
  • the reprogrammed cells of the invention can be transplanted "naked" into patients using techniques known in the art such as those described in U.S. Pat. Nos. 5,082,670 and 5,618,531, each incorporated herein by reference, or into any other suitable site in the body.
  • the reprogrammed cells can be transplanted as a mixture/solution comprising of single cells or a solution comprising a suspension of a cell aggregate.
  • Such aggregate can be approximately 10-500 micrometers in diameter, and, more preferably, about 40-50 micrometers in diameter.
  • a reprogrammed cell aggregate can comprise about 5-100, more preferably, about 5-20, cells per sphere.
  • the density of transplanted cells can range from about 10,000 to 1 ,000,000 cells per microliter, more preferably, from about 25,000 to 500,000 cells per microliter.
  • Transplantation of the reprogrammed cell of the present invention can be accomplished using techniques well known in the art as well those developed in the future.
  • the invention comprises a method for transplanting, grafting, infusing, or otherwise introducing reprogrammed cells into an animal, preferably, a human.
  • the reprogrammed cells also may be encapsulated and used to deliver biologically active molecules, according to known encapsulation technologies, including microencapsulation (see, e.g., U.S. Pat. Nos. 4,352,883; 4,353,888; and 5,084,350, herein incorporated by reference), or macroencapsulation (see, e.g., U.S. Pat. Nos. 5,284,761 ; 5,158,881 ; 4,976,859; and 4,968,733; and International Publication Nos.
  • cell number in the devices can be varied; preferably, each device contains between 10 3 -10 9 cells, most preferably, about 10 5 to 10 7 cells.
  • Several macroencapsulation devices may be implanted in the patient. Methods for the macroencapsulation and implantation of cells are well known in the art and are described in, for example, U.S. Pat. No. 6,498,018.
  • Reprogrammed cells of the present invention can also be used to express a foreign protein or molecule for a therapeutic purpose or for a method of tracking their integration and differentiation in a patient's tissue.
  • the invention encompasses expression vectors and methods for the introduction of exogenous DNA into reprogrammed cells with concomitant expression of the exogenous DNA in the reprogrammed cells such as those described, for example, in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York).
  • Embodiments of the invention also relate to a composition comprising a cell that has been produced by the methods of the invention.
  • the invention relates to a composition comprising cell that has been reprogrammed by inhibiting the activity of at least one HDAC.
  • the invention relates to a composition comprising a cell that has been reprogrammed by inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent.
  • Embodiments of the invention also relate to a reprogrammed cell that has been produced by contacting a cell with at least one HDAC inhibitor.
  • Embodiments of the invention also relate to kits for preparing the methods and compositions of the invention.
  • the kit can be used for, among other things, producing a reprogramming a cell and generating ES-like and stem cell-like cells, inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent, and inhibiting the activity of at least one HDAC.
  • the kit may comprise at least one HDAC inhibitor.
  • the kit may comprise multiple HDAC inhibitors.
  • the HDAC inhibitors can be provided in a single container or in multiple containers.
  • the kit may also comprise reagents necessary to determine if the cell has been reprogrammed including but not limited to reagents to test for the induction of a gene that contributes to a cell being pluripotent or multipotent, reagents to test for inhibition of an HDAC, and regents to test for remodeling the chromatin structure.
  • the kit may also comprise regents that can be used to differentiate the reprogrammed cell into a particular lineage or multiple lineages including but not limited to a neuron, an osteoblast, a muscle cell, an epithelial cell, and hepatic cell.
  • the kit may also contain an instructional material, which describes the use of the components provide in the kit.
  • an "instructional material” includes a publication, a recording, a diagram, or any other medium of expression that can be used to communicate the usefulness of the methods of the invention in the kit for, among other things, effecting the reprogramming of a differentiated cell.
  • the instructional material may describe one or more methods of re- and/or trans-differentiating the cells of the invention.
  • the instructional material of the kit of the invention may, for example, be affixed to a container that contains the HDAC inhibitor. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the HDAC inhibitor, or component thereof, be used cooperatively by the recipient.
  • Histone deacetylase inhibitors have been shown to acetylate histone proteins and demethylate DNA, thereby modifying chromatin structure in at least two ways.
  • the expression level of genes that contribute to a cell being pluripotent was tested in the presence and absence of a histone deacetylase inhibitor.
  • valproic acid (VPA) was used but any histone deaceytlase inhibitor can be used.
  • RNA was prepared from cultures using Trizol Reagent (Life Technologies, Gaithersburg, MD) and RNeasy Mini kit (Qiagen; Valencia, CA) with DNase I digestion according to manufacturer's protocol.
  • Total RNA (1 ⁇ g) from each sample was subjected to oligo(dT)-primed reverse transcription (Invitrogen; Carlsbad, CA).
  • Real-time PCR reactions will be performed with PCR master mix on a 7300 real-time PCR system (Applied Biosystems; Foster City, CA). For each sample, 1 ⁇ l of diluted cDNA (1 : 10) will be added as template in PCR reactions.
  • the expression level of Oct-4 and Nanog was normalized to GAPD.
  • Embryonic Taqman Low Density Array Analysis Expression levels of several genes that contribute to a cell being pluripotentail (“sternness genes") were determined using the Human Embryonic Taqman Low Density Array Analysis (TLDA). Several sternness genes were analyzed: GABRB3, LEFTB, NR6A1, PODXL, and PTEN. In addition, the expression level of the DNA methyl transferase DNMT3B was determined. The Applied Biosystems Human Embryonic TLDA, which contains 90 embryonic stem cell and developmental genes and 6 endogenous control genes, was used for quantitative real time RT-PCR to quantify relative expression levels (Applied Biosytems, Foster City, CA).
  • Bisulfite sequencing is the use of bisulfite treatment of DNA to determine the pattern of methylation.
  • Bisulfite sequencing is based on the fact that treatment of DNA with bisulfite converts cytosine residues to uracil, but leaves 5-methylcytosine residues unaffected.
  • Bisulfite treatment thus introduces specific changes in the DNA sequence that depend on the methylation status of individual cytosine residues, yielding very high-resolution information about the methylation status of a segment of DNA.
  • Methylation of pluripotent gene promoters was analyzed by bisulfite sequencing. Briefly, DNA was purified by phenolchloroform-isoamylalcohol extraction. Bisulfite conversion was performed using the EZ DNA Methylation kit following the manufacturer's protocol (Zymo Research; Orange, CA). The conversion rate of all cytosines in non-CpG dinucleotides to uracils was 100%. Converted DNA was amplified by PCR using primers for human Oct3/4, Nanog, and SOX2. PCR products were cloned into E. coli by TOPO TA cloning kit (Invitrogen; Carlsbad, CA). Ten clones of each sample were verified by sequencing with SP6 and T7 primers. The global methylation percentage for each promoter of interest and the number of methylated cytosines for a given CpG was compared among cell populations.
  • the DNA methyltransferase, DNMT3B was down-regulated.
  • Several other sternness-related genes that were not detected in control cells were induced in the VPA-treated cells, including FOXD3, NR5A2, TERT, LEFR, SFRP2, TFCP2L1, LIN28, SOX2 and XIST.
  • the first exon of the Oct-4 gene was analyzed by bisulfite sequencing.
  • Bisulfite sequencing revealed methylated cytosines in untreated (-) and treated (+) cells upstream from Oct4 (3F-3R) (see FIG. 3).
  • two cytosines in CpG dinucleotides in the promoter/first exon region of Oct4 in treated cells were demethylated (see FIG. 3). These patterns were consistent among several clones (data not shown).
  • an HDAC inhibitor can induce the expression of genes that contribute to a cell being pluripotent or multipotent, can reduce the expression of a DNA methyl transferase, and de-methylate cytosines in DNA. Additionally, the HDAC inhibitor can lead to demethylation of cytosines in promoter regions of genes that contribute to a cell being pluripotent or multipotent.
  • HDAC7 shRNA lentiviral infection The effect of HDAC7 shRNA lentiviral infection on the level of mRNA expression on Oct-4., Nanog, and Sox 2 was tested.
  • HDACl 1 shRNA lentiviral infection On the level of mRNA expression on Oct-4., Nanog, and Sox 2 also was tested.
  • Three types of human dermal fibroblasts were used: adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf).
  • HDFa adult human dermal fibroblasts
  • HDFn neonatal human dermal fibroblasts
  • HDFf fetal human dermal fibroblasts
  • Human dermal fibroblasts (HDFa, HDFn, and HDFf) were infected with shRNA lentivirus to interfere with HDAC7.
  • human dermal fibroblasts (HDFa, HDFn, and HDFf) were infected with shRNA lentivirus to interfere with HDACl 1.
  • RNA was isolated from HDFs (including puromycin selection) and applied to RT-PCR to analyze expression of target genes, e.g., Oct-4, Nanog, Sox2, various HDACs and various SIRT genes.
  • the shRNA construct included puromycin (antibiotic) resistance as a way to select cells that have been successfully transfected with the shRNA. After transfection, puromycin was added to the culture and cells that were not resistant (therefore not transfected) died, thereby leaving only transfected cells remaining in the culture.
  • Cell culture Human dermal fibroblasts were purchased from Cell
  • SEQ ID NO. 1 GCTTTCAGGATAGTCGTGA
  • SEQ ID NO. 2 AGCGAGACTTCATGGACGA
  • SEQ ID. NO.3 TGGTGGT ATACAATGCAGG
  • the human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions.
  • HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
  • RNA (1 ⁇ g) from each sample was subjected to oligo(dT)-primed reverse transcription
  • FIG. 4A The effects of HDAC7 and HDAC 11 shRNA lentiviral infection on the mRNA level of the gene Nanog are shown in FIG. 4A (HDFa), FIG. 4B (HDFn) and FIG. 4C (HDFf).
  • HDAC7 and HDACl 1 knockdown increased the level of mRNA for the gene Nanog, both in the presence and absence of puromycin (shown for adult and neonatal human dermal fibroblasts).
  • HDFa and HDFn expression of Nanog increased at least six-fold over time. The increase in the level of Nanog mRNA was seen with and without puromycin selection. As reported in FIG.
  • FIG. 5A The effects of HDAC7 and HDAC 11 shRNA lentiviral infection on the mRNA level of the gene Oct-4 are shown in FIG. 5A (HDFa), FIG. 5B (HDFn) and FIG. 5C (HDFf).
  • Both HDAC7 and HDACl 1 knockdown increased the level of mRNA for the gene Nanog in the cell types HDFa and HDFn.
  • the increase in expression of Oct-4 was observed both in the presence and absence of puromycin (FIG. 5A and FIG. 5B).
  • a more modest increase in the level of mRNA for the gene Oct-4 was observed as compared to the gene Nanog.
  • FIG.6 reports the effect of HDAC7 and HDAC 1 1 shRNA lentiviral infection on the mRNA level of Sox-2 in fetal human dermal fibroblasts. No induction in the level of mRNA for the Sox-2 gene was observed.
  • FIG. 7 reports the effects of HDAC7 shRNA lentiviral infection on the level of mRNA expression of various HDAC genes and SIRT genes. As shown in FIG. 7, the expression of HDAC 9, HDAC5 and HDACl 1 mRNA was inducted three days after HDAC7 shRNA infection. The level of HDAC7 mRNA was reduced about 50% of basal level around three days after lentiviral infection.
  • HDAC7 The inhibition of one HDAC, in this case HDAC7, led to an increase in the expression of several other HDAC genes.
  • HDACs are closely related, and have likely evolved to have redundant or at least similar functions. If one family member is inhibited, the expression of other family members may be increased to compensate for the inhibited member. HDACs play a crucial function and therefore, redundant and/or compensatory pathways may have evolved.
  • One mechanism to reprogram a cell may be to simultaneously or sequentially target multiple family members to account for the redundant and/or compensatory pathways.
  • Another mechanism to reprogram a cell may be to simultaneously or sequentially target inhibitory proteins in the same family or to target inhibitory proteins in different families of regulatory proteins.
  • HDAC7 and HDACl 1 were interfered with and the effect on the expression of various genes determined.
  • Three types of human dermal fibroblasts were used: adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf).
  • HDFs including puromycin selection
  • RT-PCR to analyze expression of target genes, e.g., Oct-4, Nanog, Sox2, various HDACs and various SIRT genes.
  • the shRNA construct included puromycin (antibiotic) resistance as a way to select cells that have been successfully transfected with the shRNA. After transfection, puromycin was added to the culture and cells that were not resistant (therefore not transfected) died, thereby leaving only transfected cells remaining in the culture.
  • SEQ ID NO. 1 GCTTTCAGGATAGTCGTGA
  • SEQ ID NO. 2 AGCGAGACTTCATGGACGA
  • shRNA construct with the following sequence was directed against HDACI l :
  • SEQ ID. NO.3 TGGTGGTATACAATGCAGG
  • the human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions.
  • HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
  • RNA (1 ⁇ g) from each sample was subjected to oligo(dT)-primed reverse transcription
  • FIG. 9 reports the effect on the mRNA expression of Oct-4 during dual or simultaneous HDAC7 and HDACl 1 shRNA interference.
  • the increase in Oct-4 expression was observed both in the presence and absence of puromycin.
  • a robust effect was observed for the cell type HDFn, and the mRNA expression was increased for Oct-4 as compared to a single knockdown of either HDAC7 or HDACl 1.
  • FIG. 11 reports the effects on the mRNA expression of various HDAC genes during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts. A robust increase in the expression of HDAC9 was observed. The expression of HDAC5 also was increased. Modest effects were observed on other genes (see FIG. 11).
  • FIG. 12 reports the effects on the mRNA expression of various HDAC genes during dual HDAC7 and HDACl 1 shRNA interference in fetal human dermal fibroblasts. A robust increase in the expression of HDAC9 was observed at day seven with puromyocin selection. The expression of various other HDAC genes was decreased at day seven with puromyocin selection (see FIG. 12).
  • FIG. 13 reports the effects on the mRNA expression of various HDAC genes during dual HDAC7 and HDAC 1 1 shRNA interference in neonatal human dermal fibroblasts. A robust increase in the expression of HDAC9 was observed at day without puromyocin selection and at day five with puromyocin selection. The expression of HDAC5 also was increased. Modest effects were observed on other genes (see FIG. 13).
  • shRNA construct can be used to inhibit the expression of genes that code for an HDAC, and can induce expression of pluripotent genes, such as Oct-4 and Nanog, which are two genes involved in reprogramming a cell. Further, these results demonstrate that inhibition of HDACs can play an essential role in restoring differentiation potential to ac cell.
  • the methods of the invention can be used to inhibit any HDAC or an HDAC related protein, either in structure or function.
  • HDAC histone deacetylase
  • a cell may be inhibited by shRNA, HDAC inhibitors, small molecule inhibitors or any combination of the above-recited.
  • HDACl 1 HDAC 1 1
  • HDFa adult human dermal fibroblasts
  • HDFn neonatal human dermal fibroblasts
  • HDFf fetal human dermal fibroblasts
  • SEQ ID NO. 1 GCTTTCAGGAT AGTCGTGA
  • the human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions.
  • HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
  • RNA (1 ⁇ g) from each sample was subjected to oligo(dT)-primed reverse transcription (Invitrogen; Carlsbad, CA). Real-time PCR reactions will be performed with PCR master mix on a 7300 real-time PCR system (Applied Biosystems; Foster
  • HDAC7a and HDACl 1 were normalized to glyceraldehyde 3-phosphate-dehydrogenase (GAPD).
  • HDAC7a was decreased, in fetal human dermal fibroblasts infected with HDAC7a shRNA (FIG. 14A). Similar results were obtained with neonatal human dermal fibroblasts (FIG. 14B) and fetal human dermal fibroblasts (FIG. 14C). The increase in expression was observed both in the presence and absence of puromycin. HDACl 1 expression was up-regulated in a compensatory fashion in all three cell types tested. Inhibiting the expression of a gene that codes for a regulatory protein, which is involved in decreasing expression of a pluripotent gene, may lead to an increase in expression of other genes coding for a regulatory protein. Multiple agents targeted to a single family of regulatory proteins or multiple families of regulatory proteins may be an efficient means to reprogram a cell. The agents include but are not limited to small molecule inhibitors and shRNA constructs.
  • DNMTl were stained and visualized for expression of pluripotent genes. Protein expression of Oct-4 and Sox-2 was analyzed in this example, but one of ordinary skill in the art will understand the methods of the invention can be used to increase expression of any gene involved in reprogramming or restoring differentiation potential to a cell.
  • the shRNA construct was obtained from Dharmacon.
  • the shRNA construct directed toward HDAC7a had the following sequence:
  • SEQ ID NO. 1 GCTTTCAGGATAGTCGTGA
  • SEQ ID NO. 2 AGCGAGACTTC ATGG ACGA
  • shRNA construct with the following sequence was directed against HDACI l :
  • SEQ ID. NO.3 TGGTGGT ATACAATGCAGG
  • the shRNA construct directed toward DNMTl had the following sequence:
  • SEQ ID NO.4 GTCTACCAGATCTTCGATA
  • the human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions.
  • HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
  • Oct3/4 pluripotency marker
  • Oct-4 protein expression was increased in fetal human dermal fibroblasts
  • FIG. 15A is a photograph of HDFf without infection
  • FIG. 15G is a photograph of human embryonic stem cells (positive control). In the negative control cells, little expression of Oct-4 protein was detected.
  • FIG. 15B is a photograph of HDFf cells infected with shRNA directed toward
  • DNMTl shRNA HDFf cells infected with HDAC7 shRNA show minimal detection of Oct-4 protein (FIG. 15C). This may be due to the processing of this particular sample.
  • DNMTl and HDAC7 shRNA produce an expression pattern very similar to human embryonic stem cells (Invitrogen, Carlsbad, CA) (FIG. 15E).
  • Oct-4 protein expression DNMT and HDACl 1 have distinct functions with regard to regulation of activation of transcription and chromatin remodeling. The inhibition of members from two separate regulatory groups resulted in a dramatic increase in the expression of Oct-4. Oct-4 protein expression was also increased in cells infected with DNMTl and HDACl 1 (FIG. 15E). Inhibition of DNMTl and multiple HDACs resulted in increase in expression of Oct-4 protein.
  • FIG. 16A is a photograph of HDFf without infection (negative control).
  • FIG. 16G is a photograph of human embryonic stem cells (FIG. 16G). In the negative control cells, little expression of Sox-2 protein was detected.
  • FIG. 16B is a photograph of HDFf cells infected with shRNA directed toward DNMTl . Nuclear staining was visible, however only a modest amount of Sox-2 protein was detected.
  • HDFf cells infected with HDAC7 and DNMTl shRNA showed minimal detection of Sox-2protein (FIG. 16C). This may be due to the processing of this particular sample.
  • the methods of the present invention can be used to reprogram a differentiated cell in the absence of somatic cell nuclear transfer (SCNT).
  • SCNT is very inefficient and has posed a significant limitation on the field of reprogramming.
  • the present methods alleviate the need for SCNT.
  • the present methods have demonstrated an increase in expression of the endogenous pluripotent genes and proteins, as opposed to measuring effects on an artificial vector with a strong reporter element.
  • An artificial vector does not have the same chromatin structure as the endogenous gene, nor does it have other genes, and promoter elements to create the environment of the genome.
  • An artificial vector does not have many of the natural elements needed to recapitulate the environment of the natural genome.
  • the results presented herein represent effects obtained from treating human cells, and measuring the effects on the endogenous gene.
  • the data presented herein demonstrate that inhibiting or altering the function of histone deacetylases is one step involved in reprogramming a differentiated cell, and restoring differentiation potential.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the activity of an HDAC with an HDAC inhibitor and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In still another embodiment, the invention relates to a method for reprogramming comprising exposing a cell to more than one agent to inhibit more than ore type of regulatory protein. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into various differentiated cell types.

Description

REPROGRAMMING A CELL BY INDUCING A PLURIPOTENT GENE THROUGH USE OF AN HDAC MODULATOR
CROSS REFERENCE TO RELATED PATENT APPLICATIONS
This application is a continuation-in-part of U.S. Patent Application No. 11/497,064, filed August 1, 2006, which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application 60/704,465, filed August 1, 2005, and also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application 61/042,890, filed April 7, 2008; U.S. Provisional Application 61/043,066, filed April 7, 2008; U.S. Provisional Application 61/042,995, filed on April 7, 2008; and U.S. Provisional Application 61/1 13,971, filed November 12, 2008, each of which is incorporated herein by reference as if set forth in its entirety.
FIELD OF THE INVENTION
[0001] Embodiments of the invention relate to the fields of cell biology, stem cells, cell differentiation, somatic cell nuclear transfer and cell-based therapeutics. More specifically, embodiments of the invention are related to methods, compositions and kits for reprogramming cells and cell-based therapeutics.
BACKGROUND OF THE INVENTION
[0002] Regenerative medicine holds great promise as a therapy for many human ailments, but also entails some difficult technical challenges, which include low cloning efficiency, a short supply of potentially pluripotent tissues, and a generalized lack of knowledge as to how to control cell differentiation and what types of embryonic stem cells can be used for selected therapies. While ES cells have tremendous plasticity, undifferentiated ES cells can form teratomas (benign tumors) containing a mixture of tissue types. In addition, transplantation of ES cells from one source to another likely would require the administration of drugs to prevent rejection of the new cells. [0003] Attempts have been made to identify new avenues for generating stem cells from tissues that are not of fetal origin. One approach involves the manipulation of autologous adult stem cells. The advantage of using autologous adult stem cells for regenerative medicine lies in the fact that they are derived from and returned to the same patient, and are therefore not subject to immune-mediated rejection. A drawback is that these cells lack the plasticity and pluripotency of ES cells and thus their potential is uncertain. Another approach is aimed at reprogramming somatic cells from adult tissues to create pluripotent ES-like cells. However, this approach has been difficult as each cell type within a multi-cellular organism has a unique epigenetic signature that is thought to become fixed once cells differentiate or exit from the cell cycle.
[0004] Cellular DNA generally exists in the form of chromatin, a complex comprising of nucleic acid and protein. Indeed, most cellular RNA molecules also exist in the form of nucleoprotein complexes. The nucleoprotein structure of chromatin has been the subject of extensive research, as is known to those of skill in the art. In general, chromosomal DNA is packaged into nucleosomes. A nucleosome comprises a core and a linker. The nucleosome core comprises an octamer of core histones (two each of H2A, H2B, H3 and H4) around which is wrapped approximately 150 base pairs of chromosomal DNA. In addition, a linker DNA segment of approximately 50 base pairs is associated with linker histone H 1. Nucleosomes are organized into a higher-order chromatin fiber and chromatin fibers are organized into chromosomes. See, for example, Wolffe "Chromatin: Structure and Function" 3.sup.rd Ed., Academic Press, San Diego, 1998.
[0005] Chromatin structure is not static, but is subject to modification by processes collectively known as chromatin remodeling. Chromatin remodeling can serve, for example, to remove nucleosomes from a region of DNA; to move nucleosomes from one region of DNA to another; to change the spacing between nucleosomes; or to add nucleosomes to a region of DNA in the chromosome. Chromatin remodeling can also result in changes in higher order structure, thereby influencing the balance between transcriptionally active chromatin (open chromatin or euchromatin) and transcriptionally inactive chromatin (closed chromatin or heterochromatin). [0006] Chromosomal proteins are subject to numerous types of chemical modification. One mechanism for the posttranslational modification of these core histories is the reversible acetylation of the epsilon-amino groups of conserved highly basic N-terminal lysine residues. The steady state of histone acetylation is established by the dynamic equilibrium between competing histone acetyltransferase(s) and histone deacetylase(s) herein referred to as HDAC.
[0007] HDACs are classified in at least four classes depending on sequence identity and domain organization: Class I: HDACl, HDAC2, HDAC3, HDAC8; Class II: HDAC4, HDAC5, HDAC6, HDAC7A, HDAC9, HDAClO; Class III: sirtuins in mammals (SIRTl , SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7); and Class IV: HDACl 1. Class I HDACs are those that most closely resemble the yeast transcriptional regulator RPD3. Class II HDACs are those that most closely resemble the yeast HDAl enzyme.
[0008] Histone acetylation and deacetylation has long been linked to transcriptional control. The reversible acetylation of histones can result in chromatin remodeling and as such can act as a control mechanism for gene transcription. In general, hyperacetylation of histones facilitates gene expression, whereas histone deacetylation is correlated with transcriptional repression. Histone acetyltransferases were shown to act as transcriptional coactivators, whereas deacetylases were found to belong to transcriptional repression pathways.
[0009] The dynamic equilibrium between histone acetylation and deacetylation is essential for normal cell growth. Inhibition of histone deacetylation results in cell cycle arrest, cellular differentiation, apoptosis and reversal of the transformed phenotype.
[0010] The development of pluripotent or totipotent cells into a differentiated, specialized phenotype is determined by the particular set of genes expressed during development. Gene expression is mediated directly by sequence-specific binding of gene regulatory proteins that can effect either positive or negative regulation. However, the ability of any of these regulatory proteins to directly mediate gene expression depends, at least in part, on the accessibility of their binding site within the cellular DNA. As discussed above, accessibility of sequences in cellular DNA often depends on the structure of cellular chromatin within which cellular DNA is packaged. [0011] Therefore, it would be useful to identify methods, compositions and kits that can induce the expression of genes required for pluripotency, including methods, compositions, and kits that can inhibit the activity of HDACs involved in repressing transcription.
BRIEF SUMMARY OF THE INVENTION
[0012] The invention relates to methods, compositions and kits for reprogramming a cell. Embodiments of the invention relate to methods comprising inducing the expression of a pluripotent or multipotent gene. In yet another embodiment, the invention further relates to producing a reprogrammed cell. In still yet another embodiment, the invention relates to a method comprising inhibiting the activity, expression or activity and expression of at least one HDAC by use of an HDAC inhibitor. In yet another embodiment, the invention relates to a method comprising altering the activity, expression or activity and expression of at least one HDAC by use of an HDAC modulator. The method further comprises inducing the expression of at least one pluripotent or multipotent gene, and reprogramming the cell. [0013] Embodiments of the invention also relate to methods for reprogramming a cell comprising contacting a cell, a population of cells, a cell culture, a subset of cells from a cell culture, a homogeneous cell culture or a heterogeneous cell culture with an HDAC modulator, inducing the expression of at least one pluripotent or multipotent gene, and reprogramming the cell. The method further comprises re-differentiating the reprogrammed cell.
[0014] In another embodiment, the invention relates to the use of an agent to inhibit the expression, activity or expression and activity of an HDAC. The agent can be any molecule or compound that can inhibit the expression, activity, or expression and activity of an HDAC including but not limited to an HDAC inhibitor, a small molecule, a nucleic acid sequence, a DNA sequence, an RNA sequence, a shRNA sequence, and RNA interference.
[0015] In another embodiment, the invention relates to the use of an agent to induce the activity, expression, or activity and expression of a protein that inhibits the activity of an HDAC. The agent can be any molecule or compound that can induce the expression, activity, or expression and activity of a protein that inhibits an HDAC including but not limited to a small molecule, a nucleic acid sequence, a DNA sequence, an RNA sequence, a shRNA sequence, and RNA interference [0016] An HDAC inhibitor can be used to inhibit the activity of an HDAC and includes but is not limited to TSA, sodium butyrate, valproic acid, vorinostat, LBH- 589, apicidin, TPX-HA analogue, CI-994, MS-275, MGCD0103, and derivatives or analogues of the above-mentioned.
[0017] In some embodiments, at least one HDAC inhibitor can inhibit at least one HDAC. In still yet another embodiment, more than one HDAC inhibitor, either simultaneously or sequentially, can inhibit at least one HDAC. An HDAC inhibitor can be directed toward an HDAC in class I, class II, class III, class IV, or an unknown or unclassified HDAC. An HDAC inhibitor can be directed toward more than one class of HDACs or all classes of HDACs. Combinations of HDAC inhibitors can inhibit more than one HDAC, and can be used simultaneously or sequentially. [0018] In another embodiment, the invention relates to a method for reprogramming a cell comprising: exposing a population of cells to an agent that inhibits activity, expression, or activity and expression of a histone deacetylase; inducing expression of a pluripotent or multipotent gene; selecting a cell that express a cell surface marker indicative of a pluripotent or multipotent cell, and expanding said selected cell to produce a population of cells, wherein differentiation potential has been restored to said cell.
[0019] In yet another embodiment, the invention relates to a method for reprogramming a cell comprising: exposing a cell to a first agent that inhibits that activity, expression or expression and activity of a HDAC; exposing said cell to a second agent that inhibits the activity, expression or expression and activity of a second regulatory protein, wherein said second regulatory protein has a distinct function from the HDAC, inducing expression of a pluripotent or multipotent gene, and selecting a cell, wherein differentiation potential has been restored to said cell. In another embodiment, the cell or population of cells may be exposed to the first and second agent simultaneously or sequentially.
[0020] In still another embodiment, the invention relates to a method comprises exposing a cell with a first phenotype to an agent that inhibits the activity, expression or activity and expression of at least one HDAC; comparing the first phenotype of the cell to a phenotype obtained after exposing the cell to said agent, and selecting the cell that has been reprogrammed. In yet another embodiment, the method comprises comparing the genotype of a cell prior to exposing the cell to said agent to a genotype of the cell obtained after exposing said cell to said agent. In still yet another embodiment, the method comprises comparing the phenotype and genotype of a cell prior to exposing the cell to an agent that inhibits the activity, expression or activity and expression of at least one HDAC to the phenotype and genotype of the cell after exposing the cell to said agent.
[0021] In still another embodiment, the method comprises culturing or expanding the selected cell to a population of cells. In yet another embodiment, the method comprises isolating a cell using an antibody that binds to a protein coded for by a pluripotent or multipotent gene or an antibody that binds to a multipotent marker or a pluripotent marker, including but not limited to SSEA3, SSEA4, Tra-1-60, and Tra-1- 81. Cells may also be isolated using any method efficient for isolating cells including but not limited to a fluorescent cell activated sorter, immunohistochemistry, and ELISA. In another embodiment, the method comprises selecting a cell that has a less differentiated state than the original cell.
[0022] In still another embodiment, the invention further comprises comparing chromatin structure of a pluripotent or multipotent gene prior to exposure to said agent to the chromatin structure obtained after exposure to said agent. [0023] In another embodiment, the invention relates to a method for reprogramming a cell comprising: exposing a cell with a first transcriptional pattern to an agent that inhibits the activity, expression or activity and expression of a HDAC; inducing expression of a pluripotent or multipotent gene; comparing the first transcriptional pattern of the cell to a transcriptional pattern obtained after exposure to said agent; and selecting a cell, wherein differentiation potential has been restored to said cell.
[0024] In still another embodiment, selecting a cell comprises identifying a cell with a transcriptional pattern that is at least 5-10%, 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, 90-94%, 95%, or 95-99% similar to an analyzed transcriptional pattern of an embryonic stem cell. The entire transcriptional pattern of an embryonic stem cell need not be compared, although it may. Instead, a subset of embryonic genes may be compared including but not limited to 1-5, 5-10, 10-25, 25-50, 50-100, 100-200, 200-500, 500-1,000, 1,000-2,000, 2,000-2,500, 2,500- 5,000, 5,000-10,000 and greater than 10,000 genes. The transcriptional patterns may be compared in a binary fashion, i.e., the comparison is made to determine if the gene is transcribed or not. In another embodiment, the rate and/or extent of transcription for each gene or a subset of genes may be compared. Transcriptional patterns can be determined using any methods known in the art including but not limited to RT-PCR, quantitative PCR, a microarray, southern blot and hybridization. [0025] Embodiments of the invention also include methods comprising treating a variety of diseases using a reprogrammed cell produced according to the methods disclosed herein. In yet another embodiment, the invention also relates to therapeutic uses for reprogrammed cells and reprogrammed cells that have been re-differentiated. [0026] Embodiments of the invention also relate to a reprogrammed cell produced by the methods of the invention. The reprogrammed cell can be re-differentiated into a single lineage or more than one lineage. The reprogrammed cell can be multipotent or pluripotent.
[0027] In yet another embodiment, the invention relates to an enriched population of reprogrammed cells produced according to a method comprising the steps of: exposing a population of cells to an agent that inhibits activity, expression of activity and expression of a histone deacetylase; inducing expression of a pluripotent or multipotent gene; selecting a cell that express a cell surface marker indicative of a pluripotent or multipotent cell, and expanding said selected cell to produce a population of cells, wherein differentiation potential has been restored to said cell [0028] In still another embodiment, the reprogrammed cell expresses a cell surface marker indicative of a pluripotent cell selected from the group consisting of: SSEA3, SSEA4, Tra-1-60, and Tra-1-81. In still another embodiment, the reprogrammed cell expresses a pluripotent gene including but not limited to Oct-4, Sox-2 and Nanog. In yet another embodiment, the reprogrammed cells account for at least 5-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, 90-95%, 96-98%; or at least 99% of the enriched population of cells [0029] Embodiments of the invention also relate to kits for preparing the methods and compositions of the invention. The kit can be used for, among other things, reprogramming a cell and generating ES-like and stem cell-like cells.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG. 1 is a bar graph reporting the up-regulation of Oct-4 in primary human lung cells treated with valproic acid (VPA).
[0031] FIG. 2 is a bar graph reporting the up-regulation of several genes, which confer stem-cell like characteristics, in primary human lung cells treated with an
HDAC inhibitor (VPA).
[0032] FIG. 3 is an illustration reporting the demethylation of two cytosines in the first exon of Oct-4 in cells treated with VPA.
[0033] FIG. 4A is a graph reporting the effects on the gene Nanog as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in adult human dermal fibroblasts. FIG. 4B is a graph reporting the effects on the gene
Nanog as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in neonatal human dermal fibroblasts. FIG. 4C is a graph reporting the effects on the gene Nanog as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in fetal human dermal fibroblasts.
[0034] FIG. 5A is a graph reporting the effects on the gene Oct-4 as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in adult human dermal fibroblasts. FIG. 5B is a graph reporting the effects on the gene
Oct-4 as measured by fold-change in mRNA expression during HDAC7 or HDACl 1 shRNA interference in neonatal human dermal fibroblasts. FIG. 5C is a graph reporting the effects on the gene Oct-4 as measured by fold-change in mRNA expression during HDAC7 or HDAC 11 shRNA interference in fetal human dermal fibroblasts.
[0035] FIG. 6 is a graph reporting the effects on the gene Sox-2 as measured by fold-change in mRNA expression during HDAC7 or HDAC 1 1 shRNA interference in fetal human dermal fibroblasts. [0036] FIG 7 is a graph reporting the effects on various HDAC and SIRT genes as measured by mRNA expression during HDAC7 shRNA interference in human dermal fibroblasts.
[0037] FIG. 8 is a graph reporting the effects on the gene Nanog as measured by fold-change in mRNA expression during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf)-
[0038] FIG. 9 is a graph reporting the effects on the gene Oct-4 as measured by fold-change in mRNA expression during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf).
[0039] FIG. 10 is a graph reporting the effects on the gene Sox-2 as measured by fold-change in mRNA expression during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf).
[0040] FIG. 1 1 is a graph reporting the effects on various HDAC genes and SIRT genes as measured by fold change in mRNA expression during dual HDAC7 and
HDACl 1 shRNA interference in adult human dermal fibroblasts.
[0041] FIG. 12 is a graph reporting the effects on various HDAC genes and SIRT genes as measured by fold change in mRNA expression during dual HDAC7 and
HDACl 1 shRNA interference in fetal human dermal fibroblasts.
[0042] FIG. 13 is a graph reporting the effects on various HDAC genes and SIRT genes as measured by fold change in mRNA expression during dual HDAC7 and
HDACl 1 shRNA interference in neonatal human dermal fibroblasts.
[0043] FIG. 14A is a graph reporting the effect of HDAC7a shRNA on the expression of HDAC7a and HDAC 11 in adult human dermal fibroblasts. Data for cells grown both in the absence and presence of puromycin are reported.
[0044] FIG. 14B is a graph reporting the effect of HDAC7a shRNA on the expression of HDAC7a and HDAC 11 in neonatal human dermal fibroblasts. Data for cells grown both in the absence and presence of puromycin are reported.
[0045] FIG. 14C is a graph reporting the effect of HDAC7a shRNA on the expression of HDAC7a and HDACl 1 in fetal human dermal fibroblasts. [0046] FIG. 15 A is a photograph of fetal human dermal fibroblasts.
[0047] FIG. 15B is a photograph of fetal human dermal fibroblasts infected with
DNMTl shRNA.
[0048] FIG. 15C is a photograph of fetal human dermal fibroblasts infected with
HDAC7 shRNA.
[0049] FIG. 15D is a photograph of fetal human dermal fibroblasts infected with
DNMTl and HDAC7 shRNA.
[0050] FIG. 15E is a photograph of fetal human dermal fibroblasts infected with
DNMTl and HDAC 11 shRNA.
[0051] FIG. 15F is a photograph of fetal human dermal fibroblasts infected with
HDACl 1 and HDAC7 shRNA.
[0052] FIG. 15G is a photograph of human embryonic stem cells.
[0053] FIG. 16A is a photograph of fetal human dermal fibroblasts.
[0054] FIG. 16B is a photograph of fetal human dermal fibroblasts infected with
DNMTl shRNA.
[0055] FIG. 16C is a photograph of fetal human dermal fibroblasts infected with
DNMTl and HDAC7 shRNA.
[0056] FIG. 16D is a photograph of fetal human dermal fibroblasts infected with
DNMTl and HDACl 1 shRNA.
[0057] FIG. 16E is a photograph of fetal human dermal fibroblasts infected with
HDAC7 shRNA.
[0058] FIG. 16F is a photograph of fetal human dermal fibroblasts infected with
HDACl 1 and HDAC7 shRNA.
[0059] FIG. 16G is a photograph of human embryonic stem cells.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT [0060] Definitions
[0061] The numerical ranges in this disclosure are approximate, and thus may include values outside of the range unless otherwise indicated. Numerical ranges include all values from and including the lower and the upper values, in increments of one unit, provided that there is a separation of at least two units between any lower value and any higher value. As an example, if a compositional, physical or other property, such as, for example, molecular weight, viscosity, melt index, etc., is from
100 to 1,000, it is intended that all individual values, such as 100, 101, 102, etc., and sub ranges, such as 100 to 144, 155 to 170, 197 to 200, etc., are expressly enumerated.
For ranges containing values which are less than one or containing fractional numbers greater than one (e.g., 1.1, 1.5, etc.), one unit is considered to be 0.0001, 0.001, 0.01 or
0.1, as appropriate. For ranges containing single digit numbers less than ten {e.g., 1 to
5), one unit is typically considered to be 0.1. These are only examples of what is specifically intended, and all possible combinations of numerical values between the lowest value and the highest value enumerated, are to be considered to be expressly stated in this disclosure. Numerical ranges are provided within this disclosure for, among other things, relative amounts of components in a mixture, and various temperature and other parameter ranges recited in the methods.
[0062] "Cell" or "cells," unless specifically limited to the contrary, includes any somatic cell, embryonic stem (ES) cell, adult stem cell, an organ specific stem cell, nuclear transfer (NT) units, and stem-like cells. The cell or cells can be obtained from any organ or tissue. The cell or cells can be human or other animal. For example, a cell can be mouse, guinea pig, rat, cattle, horses, pigs, sheep, goats, etc. A cell also can be from non-human primates.
[0063] "Culture Medium" or "Growth Medium" means a suitable medium capable of supporting growth of cells.
[0064] "Differentiation" means the process by which cells become structurally and functionally specialized during embryonic development.
[0065] "Epigenetics" means the state of DNA with respect to heritable changes in function without a change in the nucleotide sequence. Epigenetic changes can be caused by modification of the DNA, such as by methylation and demethylation, without any change in the nucleotide sequence of the DNA.
[0066] "Histone" means a class of protein molecules found in chromosomes responsible for compacting DNA enough so that it will fit within a nucleus.
[0067] "Histone deacetylase inhibitor" and "inhibitor of histone deacetylase" mean a compound that is capable of interacting with a histone deacetylase and inhibiting its enzymatic activity. "Inhibiting histone deacetylase activity" means reducing the ability of a histone deacetylase to remove an acetyl group from a suitable substrate, such as a histone, or other protein. In some embodiments, such reduction of histone deacetylase activity is at least about 10-25%, in other embodiments at least about 50%, in other embodiments at least about 75%, and still in other embodiments at least about 90%. In still yet other embodiments, histone deacetylase activity is reduced by at least 95% and in other embodiments by at least 99%.
[0068] "Knock down" means to suppress the expression of a gene in a gene- specific fashion. A cell that has one or more genes "knocked down," is referred to as a knock-down organism or simply a "knock-down."
[0069] "Pluripotent" means capable of differentiating into cell types of the 3 germ layers or primary tissue types.
[0070] "Pluripotent gene" means a gene that contributes to a cell being pluripotent. [0071] "Pluripotent cell cultures" are said to be "substantially undifferentiated" when that display morphology that clearly distinguishes them from differentiated cells of embryo or adult origin. Pluripotent cells typically have high nuclear/cytoplasmic ratios, prominent nucleoli, and compact colony formation with poorly discernable cell junctions, and are easily recognized by those skilled in the art. It is recognized that colonies of undifferentiated cells can be surrounded by neighboring cells that are differentiated. Nevertheless, the substantially undifferentiated colony will persist when cultured under appropriate conditions, and undifferentiated cells constitute a prominent proportion of cells growing upon splitting of the cultured cells. Useful cell populations described in this disclosure contain any proportion of substantially undifferentiated pluripotent cells having these criteria. Substantially undifferentiated cell cultures may contain at least about 20%, 40%, 60%, or even 80% undifferentiated pluripotent cells (in percentage of total cells in the population). [0072] "Regulatory protein" means any protein that regulates a biological process, including regulation in a positive and negative direction. The regulatory protein can have direct or indirect effects on the biological process, and can either exert affects directly or through participation in a complex.
[0073] "Reprogramming" means removing epigenetic marks in the nucleus, followed by establishment of a different set of epigenetic marks. During development of multicellular organisms, different cells and tissues acquire different programs of gene expression. These distinct gene expression patterns appear to be substantially regulated by epigenetic modifications such as DNA methylation, histone modifications and other chromatin binding proteins. Thus each cell type within a multicellular organism has a unique epigenetic signature that is conventionally thought to become "fixed" and immutable once the cells differentiate or exit the cell cycle. However, some cells undergo major epigenetic "reprogramming" during normal development or certain disease situations.
[0074] "Totipotent" means capable of developing into a complete embryo or organ.
[0075] Embodiments of the invention relate to methods comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In another embodiment, the invention relates to methods comprising inducing the expression of at least one gene that contributes to a cell being multipotent. In some embodiments, the methods comprise inducing expression of at least one gene that contributes to a cell being pluripotent or multipotent and producing reprogrammed cells that are capable of directed differentiation into at least one lineage. [0076] Embodiments of the invention also relate to methods comprising modifying chromatin structure, and reprogramming a cell to be pluripotent or multipotent. In yet another embodiment, modifying chromatin structure comprises inhibiting the activity of an HDAC.
[0077] In another embodiment, the method comprises inhibiting the activity of an HDAC, and inducing expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the activity of an HDAC and producing a reprogrammed cell. [0078] In still another embodiment, the invention relates to a method for reprogramming a cell comprising: exposing a cell to an agent that inhibits the activity, expression or activity and expression of an HDAC, inducing expression of a pluripotent or multipotent gene; and selecting a cell, wherein differentiation potential has been restored to said cell. The pluripotent or multipotent gene may be induced by any fold increase in expression including but not limited to 0.25-0.5, 0.5-1, 1.0-2.5, 2.5-5, 5-10, 10-15, 15-20, 20-40, 40-50, 50-100, 100-200, 200-500, and greater than 500. In another embodiment, the method comprises plating differentiated cells, exposing said differentiated cell to an agent that inhibits the activity, expression, or activity and expression of an HDAC, culturing said cells, and identifying a cell that has been reprogrammed.
[0079] In another embodiment, the invention relates to a method for reprogramming a cell comprising exposing a cell to an agent that induces the expression, activity, or expression and activity a regulatory protein that inhibits the activity of an HDAC, inducing expression of a pluripotent or multipotent gene; and selecting a cell, wherein differentiation potential has been restored to said cell. The activity or expression of a regulatory protein can be increased by any amount including but not limited to 1-5%, 5-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, 90-95%, and 95-99%, 99-200%, 200-300%, 300-400%, 400-500% and greater than 500%.
[0080] In yet another embodiment, the method further comprises selecting a cell using an antibody directed to a protein or a fragment of a protein coded for by a pluripotent or multipotent gene or a pluripotent surface marker. Any type of antibody can be used including but not limited to a monoclonal, a polyclonal, a fragment of an antibody, a peptide mimetic, an antibody to the active region, and an antibody to the conserved region of a protein
[0081] In still another embodiment, the method further comprises selecting a cell using a reporter driven by a pluripotent or mulitpotent gene or a pluripotent or mulitpotent surface marker. Any type of reporter can be used including but not limited to a fluorescent protein, green fluorescent protein, cyan fluorescent protein (CFP), a yellow fluorescent protein (YFP), bacterial luciferase, jellyfish aequorin, enhanced green fluorescent protein, chloramphenicol acetyltransferase (CAT), dsRED, β- galactosidase, and alkaline phosphatase.
[0082] In still another embodiment, the method further comprises selecting a cell using resistance as a selectable marker including but not limited to resistance to an antibiotic, a fungicide, puromycin, hygromycin, dihydrofolate reductase, thymidine kinase, neomycin resistance (neo), G418 resistance, mycophenolic acid resistance (gpt), zeocin resistance protein and streptomycin.
[0083] In still another embodiment, the method further comprises comparing the chromatin structure of a pluripotent or multipotent gene of a cell, prior to exposing said cell to an agent that inhibits the activity, expression or activity and expression of an HDAC, to the chromatin structure of a pluripotent or multipotent gene obtained after treatment with said agent. Any aspect of chromatin structure can be compared including but not limited to euchromatin, heterochromatin, histone acetylation, histone methylation, the presence and absence of histone or histone components, the location of histones, the arrangement of histones, and the presence or absence of regulatory proteins associated with chromatin. The chromatin structure of any region of a gene may be compared including but not limited to an enhancer element, an activator element, a promoter, the TATA box, regions upstream of the start site of transcription, regions downstream of the start site of transcription, exons and introns. [0084] In still another embodiment, the method comprises inhibiting the activity of at least one HDAC, demethylating at least one cytosine in a CpG dinucleotide, and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent.
[0085] In yet another embodiment, the method comprises contacting a cell with an HDAC inhibitor; inhibiting the activity of an HDAC; and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method further comprises producing a reprogrammed cell. The reprogrammed cell can be pluripotent or multipotent.
[0086] An HDAC inhibitor of the methods, compositions and kits of the invention may interact with any HDAC. For example, an HDAC inhibitor of the invention may interact with an HDAC from one of the four known classes of HDACs. An HDAC inhibitor of the invention may interact with an HDAC of class I, class II, class III, or class IV. An HDAC inhibitor may interact with one specific class of HDACs, all classes of HDACS, or with multiple classes of HDACs including but not limited class I and class II; class I and class III; class I and class IV; class II and class III; class II and class IV; class HI and class IV; class I, II and III; class II, III and IV; and class I, II, III and IV. An HDAC inhibitor may also interact with HDACs that do not fall into one of the known classes.
[0087] An HDAC inhibitor may have an irreversible mechanism of action or a reversible mechanism of action. An HDAC inhibitor can have any binding affinity including but not limited to millimolar (mM), micromolar (μM), nanomolar (nM), picomolar (pM), and fentamolar (fM). [0088] Preferably, such inhibition is specific, i.e., the histone deacetylase inhibitor, reduces the ability of a histone deacetylase to remove an acetyl group from a histone at a concentration that is lower than the concentration of the inhibitor that is required to produce another, unrelated biological effect. Preferably, the concentration of the inhibitor required for histone deacetylase inhibitory activity is at least 2-fold lower, more preferably at least 5 -fold lower, even more preferably at least 10-fold lower, and most preferably at least 20-fold lower than the concentration required to produce an unrelated biological effect.
[0089] In another embodiment, the HDAC inhibitor may act by binding to the zinc containing catalytic domain of the HDACs. HDAC inhibitors with this mechanism of action fall into several groupings: (i) hyroxamic acids, such as Trichostatin A; (ii) cyclic tetrapeptides; (iii) benzamides; (iv) electrophilic ketones; and (v) the aliphatic acid group of compounds such as phenylbutyrate and valproic acid. [0090] In yet another embodiment, the HDAC inhibitor can be directed toward the sirtuin Class III HDACs, which are NAD+ dependent and include but are not limited to nicotinamide, derivatives of NAD, dihydrocoumarin, naphthopyranone, and 2- hydroxynaphaldehydes .
[0091] In yet another embodiment, the HDAC inhibitor can alter the degree of acetylation of nonhistone effector molecules and thereby increase the transcription of genes. HDAC inhibitors of the methods, compositions, and kits of the invention should not be considered to act solely as enzyme inhibitors of HDACs. A large variety of nonhistone transcription factors and transcriptional co-regulators are known to be modified by acetylation, including but not limited to ACTR, cMyb, p300, CBP, E2F1, EKLF, FEN 1, GATA, HNF-4, HSP90, Ku70, NFKB, PCNA, p53, RB, Runx, SFl Sp3, STAT, TFIIE, TCF, and YYl. The activity of any transcription factor or protein involved in activating transcription, which is acetylated, could be increased with the methods of the invention.
[0092] Table I provides a representative list of compounds that can function as an HDAC inhibitor. The reference to "Isotype" in Table I is meant to merely provide insight as to whether the compound has a preference for a particular class of HDAC. Listing a specific isotype or class of HDAC should not be construed to mean that the compound only has affinity for that isotype or class. HDAC inhibitors of the present invention include derivatives and analogues of any HDAC inhibitor herein mentioned. [0093] Butyric acid, or butyrate, was the first HDAC inhibitor to be identified. However, in millimolar concentrations, butyrate may not be specific for HDAC, it also may inhibit phosphorylation and methylation of nucleoproteins as well as DNA methylation. The analogue, phenylbutyrate, acts in a similar manner. More specific are trichostatin A (TSA) and trapoxin (TPX). TPX and TSA have emerged as inhibitors of histone deacetylases. TSA reversibly inhibits, whereas TPX irreversibly binds to and inactivates HDAC enzymes. Unlike butyrate, nonspecific inhibition of other enzyme systems has not yet been reported for TSA or TPX. [0094] Valproic acid also inhibits histone deacetylase activity. VPA is a known drug with multiple biological activities that depend on different molecular mechanisms of action. VPA is an antiepileptic drug. VPA is teratogenic. When used as antiepileptic drug during pregnancy, VPA may induce birth defects (neural tube closure defects and other malformations) in a few percent of born children. In mice, VPA is teratogenic in the majority of mouse embryos when properly dosed. VPA activates a nuclear hormone receptor (PPAR-delta.).
[0095] Table I. A representative list of compounds that can function as an HDAC inhibitor.
Figure imgf000019_0001
Figure imgf000020_0001
[0096] A variety of HDAC inhibitors also are available from Sigma Aldrich (St. Louis, MO) including but not limited to APHA Compound; Apicidin; Depudecin; Scriptaid; Sirtinol; and Trichostatin A. Further, additional HDAC inhibitors are available from Vinci-Biochem (Italy) including but not limited to 5-Aza-2'- deoxycytidine; CAY10398; CAY10433; ό-Chloro^SAΘ-tetrahydro-lH-carbazole-l- carboxamide; HC Toxin; ITSAl ; M344; MC 1293; MS-275; Oxamflatin; PXDlOl ; SAHA; Scriptaid; Sirtinol; Splitomicin. Dexamethasone may also be used in combination with any HDAC inhibitor. For example, a composition comprising dexamethasone and to 5-Aza-2'-deoxycytidine can be used.
[0097] Any number, any combination and any concentration of HDAC inhibitors can be used, including but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1-15, 16-20, and 21-25 HDAC inhibitors. One or more than one family of inhibitory proteins may be inhibited. One or more than one mechanism of inhibition may be used including but not limited to small molecule inhibitors, HDAC inhibitors, shRNA, RNA interference, and small interfering RNA.
[0098] In yet another embodiment, the invention relates to a method of reprogramming a cell comprising inhibiting two or more inhibitory proteins that function in a compensatory pathway. In another embodiment, the invention relate to a method of reprogramming a cell comprising inhibiting two or more proteins that function in a redundant pathway. In still another embodiment, the invention relates to a method of reprogramming a cell comprising inhibiting one or HDAC proteins, and inhibiting one or more proteins that functions to compensate for the inhibited HDAC. The inhibition of one inhibitory protein, e.g, an HDAC, can lead to an increase in the expression of one or more other inhibitory proteins. Inhibiting the expression of the redundant, compensatory, or the redundant and compensatory proteins can be accomplished using any suitable method including but not limited to shRNA, RNA interference, HDAC inhibitors, and small molecule inhibitors. [0099] In still another embodiment, the invention relates to methods for reprogramming a cell comprising inhibiting the expression, activity, or the expression and activity of an inhibitory protein, wherein the inhibition of said inhibitory protein does not cause an increase in the expression, activity, or expression and activity of other inhibitory proteins.
[00100] In yet another embodiment, the invention relates to a method for reprogramming a cell comprising inhibiting the expression, activity, or the expression and activity of an inhibitory protein, wherein the inhibition of said inhibitory protein does not cause an increase in the expression, activity, or expression and activity of a compensatory protein.
[00101] In yet another embodiment, the invention relates to a method for reprogramming a cell comprising inhibiting the expression, activity, or the expression and activity of an inhibitory protein, wherein the inhibition of said inhibitory protein does not cause an increase in the expression, activity, or expression and activity of a redundant protein.
[00102] In still another embodiment, the invention relates to a method for reprogramming a cell comprising: exposing a cell to an agent that inhibits that activity, expression or expression and activity of more than one regulatory protein. The regulatory protein can be of the same family or a distinct protein family member. In yet another embodiment, the invention relates to a method for reprogramming a cell comprising: exposing a cell to an agent that inhibits that activity, expression or expression and activity of a first regulatory protein; exposing said cell to a second agent that inhibits the activity, expression or expression and activity of a second regulatory protein, wherein said second regulatory protein has a distinct function from the first regulatory protein. The first and second regulatory proteins can be any protein involved in regulating or altering expression of proteins including but not limited to a histone deacetylase, a histone acetyltransferase, a lysine methyltransferase, a histone methyltransferase, a Trichostatin A, a histone demethylase, a lysine demethylase, a sirtuin, and a sirtuin activator, nuclear receptors, orphan nuclear receptors, Esrrβ and Esrrγ.
[00103] A reprogrammed cell produced by the methods of the invention may be pluripotent or multipotent. A reprogrammed cell produced by the methods of the invention can have a variety of different properties including embryonic stem cell like properties. For example, a reprogrammed cell may be capable of proliferating for at least 10, 15, 20, 30, or more passages in an undifferentiated state. In other forms, a reprogrammed cell can proliferate for more than a year without differentiating. Reprogrammed cells can also maintain a normal karyotype while proliferating and/or differentiating. Some reprogrammed cells also can be cells capable of indefinite proliferation in vitro in an undifferentiated state. Some reprogrammed cells also can maintain a normal karyotype through prolonged culture. Some reprogrammed cells can maintain the potential to differentiate to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture. Some reprogrammed cells can form any cell type in the organism. Some reprogrammed cells can form embryoid bodies under certain conditions, such as growth on media that do not maintain undifferentiated growth. Some reprogrammed cells can form chimeras through fusion with a blastocyst, for example.
[00104] Reprogrammed cells can be defined by a variety of markers. For example, some reprogrammed cells express alkaline phosphatase. Some reprogrammed cells express SSEA-I, SSEA-3, SSEA-4, TRA- 1-60, and/or TRA- 1-81. Some reprogrammed cells express Oct 4, Sox2, and Nanog. It is understood that some reprogrammed cells will express these at the mRNA level, and still others will also express them at the protein level, on for example, the cell surface or within the cell. [00105] A reprogrammed cell can have any combination of any reprogrammed cell property or category or categories and properties discussed herein. For example, a reprogrammed cell can express alkaline phosphatase, not express SSEA-I, proliferate for at least 20 passages, and be capable of differentiating into any cell type. Another reprogrammed cell, for example, can express SSEA-I on the cell surface, and be capable of forming endoderm, mesoderm, and ectoderm tissue and be cultured for over a year without differentiation.
[00106] A reprogrammed cell can be alkaline phosphatase (AP) positive, SSEA-I positive, and SSEA-4 negative. A reprogrammed cell also can be Nanog positive, Sox2 positive, and Oct-4 positive. A reprogrammed cell also can be Tell positive, and Tbx3 positive. A reprogrammed cell can also be Cripto positive, Stellar positive and Dazl positive. A reprogrammed cell can express cell surface antigens that bind with antibodies having the binding specificity of monoclonal antibodies TRA- 1-60 (ATCC HB-4783) and TRA- 1-81 (ATCC HB-4784). Further, as disclosed herein, a reprogrammed cell can be maintained without a feeder layer for at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 passages or for over a year.
[00107] A reprogrammed cell may have the potential to differentiate into a wide variety of cell types of different lineages including fibroblasts, osteoblasts, chondrocytes, adipocytes, skeletal muscle, endothelium, stroma, smooth muscle, cardiac muscle, neural cells, hemiopoetic cells, pancreatic islet, or virtually any cell of the body. A reprogrammed cell may have the potential to differentiate into all cell lineages. A reprogrammed cell may have the potential to differentiate into any number of lineages including 1, 2, 3, 4, 5, 6-10, 1 1-20, 21-30, and greater than 30 lineages. [00108] Any gene that contributes to a cell being pluripotent or multipotent may be induced by the methods of the invention including but not limited to glycine N- methyltransferase (Gnmt), Octamer-4 (Oct4), Nanog, SRY (sex determining region Y)-box 2 (also known as Sox2), Myc, REX-I (also known as Zfp-42), Integrin α-6, Rox-1, LIF-R, TDGFl (CRIPTO), Fragilis, SALL4 (sal-like 4), GABRB3, LEFTB, NR6A1, PODXL, PTEN, Leukocyte cell derived chemotaxin 1 (LECTl), BUBl, and Krϋppel-like factors (KIf) such as Klf4 and Klf5. Any number of genes that contribute to a cell being pluripotent or multipotent can be induced by the methods of the invention including but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1-20, 21-30, 31-40, 41-50, and greater than 50 genes.
[00109] Further, Ramalho-Santos et al. (Science 298, 597 (2002)), Ivanova et al. (Science 298, 601 (2002)) and Fortunel et al. (Science 302, 393b (2003)) each compared three types of stem cells and identified a list of commonly expressed "sternness" genes, proposed to be important for conferring the functional characteristics of stem cells. Any of the genes identified in the above-mentioned studies may be induced by the methods of the invention. Table II provides a list of genes thought to be involved in conferring the functional characteristics of stem cells. In addition to the genes listed in Table II, 93 expressed sequence tags (EST) clusters with little or no homology to known genes were also identified by Ramalho-Santos et al. and Ivanova et al, and are included within the methods of the invention. 110] Table II. Genes implicated in conferring stem cell characteristics
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
[00111] Embodiments of the invention also relate to methods for reprogramming a cell comprising modifying chromatin structure of a gene, and inducing the expression of said gene. In another embodiment, the method comprises modifying the chromatin structure of a pluripotent or multipotent gene. In still yet another embodiment, the method further comprises modifying the chromatin structure by modifying a histone. Modifying a histone includes but is not limited to acetylation; methylation; demethylation; phosphorylation; ubiquitination; sumoylation; ADP-ribosylation; deimination and proline isomerization.
[00112] Embodiments of the invention also include methods for treating a variety of diseases using a reprogrammed cell produced according to the methods disclosed herein. The skilled artisan would appreciate, based upon the disclosure provided herein, the value and potential of regenerative medicine in treating a wide plethora of diseases including, but not limited to, heart disease, diabetes, skin diseases and skin grafts, spinal cord injuries, Parkinson's disease, multiple sclerosis, Alzheimer's disease, and the like. The invention encompasses methods for administering reprogrammed cells to an animal, including humans, in order to treat diseases where the introduction of new, undamaged cells will provide some form of therapeutic relief. [00113] The skilled artisan will readily understand that reprogrammed cells can be administered to an animal as a re-differentiated cell, for example, a neuron, and will be useful in replacing diseased or damaged neurons in the animal. Additionally, a reprogrammed cell can be administered to the animal and upon receiving signals and cues from the surrounding milieu, can re-differentiate into a desired cell type dictated by the neighboring cellular milieu. Alternatively, the cell can be re-differentiated in vitro and the differentiated cell can be administered to a mammal in need there of. [00114] The reprogrammed cells can be prepared for grafting to ensure long term survival in the in vivo environment. For example, cells can be propagated in a suitable culture medium, such as progenitor medium, for growth and maintenance of the cells and allowed to grow to confluence. The cells are loosened from the culture substrate using, for example, a buffered solution such as phosphate buffered saline (PBS) containing 0.05% trypsin supplemented with 1 mg/ml of glucose; 0.1 mg/ml of MgCl.sub.2, 0.1 mg/ml CaCl.sub.2 (complete PBS) plus 5% serum to inactivate trypsin. The cells can be washed with PBS using centrifugation and are then resuspended in the complete PBS without trypsin and at a selected density for injection.
[00115] Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampoules or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
[00116] The invention also encompasses grafting reprogrammed cells in combination with other therapeutic procedures to treat disease or trauma in the body, including the CNS, PNS, skin, liver, kidney, heart, pancreas, and the like. Thus, reprogrammed cells of the invention may be co-grafted with other cells, both genetically modified and non-genetically modified cells which exert beneficial effects on the patient, such as chromaffin cells from the adrenal gland, fetal brain tissue cells and placental cells. Therefore the methods disclosed herein can be combined with other therapeutic procedures as would be understood by one skilled in the art once armed with the teachings provided herein.
[00117] The reprogrammed cells of the invention can be transplanted "naked" into patients using techniques known in the art such as those described in U.S. Pat. Nos. 5,082,670 and 5,618,531, each incorporated herein by reference, or into any other suitable site in the body.
[00118] The reprogrammed cells can be transplanted as a mixture/solution comprising of single cells or a solution comprising a suspension of a cell aggregate. Such aggregate can be approximately 10-500 micrometers in diameter, and, more preferably, about 40-50 micrometers in diameter. A reprogrammed cell aggregate can comprise about 5-100, more preferably, about 5-20, cells per sphere. The density of transplanted cells can range from about 10,000 to 1 ,000,000 cells per microliter, more preferably, from about 25,000 to 500,000 cells per microliter. [00119] Transplantation of the reprogrammed cell of the present invention can be accomplished using techniques well known in the art as well those developed in the future. The invention comprises a method for transplanting, grafting, infusing, or otherwise introducing reprogrammed cells into an animal, preferably, a human. [00120] The reprogrammed cells also may be encapsulated and used to deliver biologically active molecules, according to known encapsulation technologies, including microencapsulation (see, e.g., U.S. Pat. Nos. 4,352,883; 4,353,888; and 5,084,350, herein incorporated by reference), or macroencapsulation (see, e.g., U.S. Pat. Nos. 5,284,761 ; 5,158,881 ; 4,976,859; and 4,968,733; and International Publication Nos. WO 92/19195; WO 95/05452, all of which are incorporated herein by reference). For macroencapsulation, cell number in the devices can be varied; preferably, each device contains between 103 -109 cells, most preferably, about 105 to 107 cells. Several macroencapsulation devices may be implanted in the patient. Methods for the macroencapsulation and implantation of cells are well known in the art and are described in, for example, U.S. Pat. No. 6,498,018. [00121] Reprogrammed cells of the present invention can also be used to express a foreign protein or molecule for a therapeutic purpose or for a method of tracking their integration and differentiation in a patient's tissue. Thus, the invention encompasses expression vectors and methods for the introduction of exogenous DNA into reprogrammed cells with concomitant expression of the exogenous DNA in the reprogrammed cells such as those described, for example, in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York).
[00122] Embodiments of the invention also relate to a composition comprising a cell that has been produced by the methods of the invention. In another embodiment, the invention relates to a composition comprising cell that has been reprogrammed by inhibiting the activity of at least one HDAC. In yet another embodiment, the invention relates to a composition comprising a cell that has been reprogrammed by inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent.
[00123] Embodiments of the invention also relate to a reprogrammed cell that has been produced by contacting a cell with at least one HDAC inhibitor. [00124] Embodiments of the invention also relate to kits for preparing the methods and compositions of the invention. The kit can be used for, among other things, producing a reprogramming a cell and generating ES-like and stem cell-like cells, inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent, and inhibiting the activity of at least one HDAC. The kit may comprise at least one HDAC inhibitor. The kit may comprise multiple HDAC inhibitors. The HDAC inhibitors can be provided in a single container or in multiple containers. [00125] The kit may also comprise reagents necessary to determine if the cell has been reprogrammed including but not limited to reagents to test for the induction of a gene that contributes to a cell being pluripotent or multipotent, reagents to test for inhibition of an HDAC, and regents to test for remodeling the chromatin structure. [00126] The kit may also comprise regents that can be used to differentiate the reprogrammed cell into a particular lineage or multiple lineages including but not limited to a neuron, an osteoblast, a muscle cell, an epithelial cell, and hepatic cell. [00127] The kit may also contain an instructional material, which describes the use of the components provide in the kit. As used herein, an "instructional material" includes a publication, a recording, a diagram, or any other medium of expression that can be used to communicate the usefulness of the methods of the invention in the kit for, among other things, effecting the reprogramming of a differentiated cell. Optionally, or alternately, the instructional material may describe one or more methods of re- and/or trans-differentiating the cells of the invention. The instructional material of the kit of the invention may, for example, be affixed to a container that contains the HDAC inhibitor. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the HDAC inhibitor, or component thereof, be used cooperatively by the recipient. [00128] The invention is now described with reference to the following Examples. These Examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these Examples, but rather should be construed to encompass any and all variations that become evident as a result of the teaching provided herein. All references including but not limited to U.S. patents, allowed U.S. patent applications, or published U.S. patent applications are incorporated within this specification by reference in their entirety.
[00129] EXAMPLES
[00130] The following examples are illustrative only and are not intended to limit the scope of the invention as defined by the claims.
[00131] Example 1:
[00132] Histone deacetylase inhibitors have been shown to acetylate histone proteins and demethylate DNA, thereby modifying chromatin structure in at least two ways. The expression level of genes that contribute to a cell being pluripotent was tested in the presence and absence of a histone deacetylase inhibitor. In the present example, valproic acid (VPA) was used but any histone deaceytlase inhibitor can be used. [00133] Methods
[00134] Cell culture. Primary human lung cells were purchased from Cell Applications (San Diego, CA), and were maintained at 370C in 95% humidity and 5% CO2 in Dulbecco's modified eagle medium (DMEM, Hyclone) containing 10 % fetal bovine serum (FBS, Hyclone) and 0.5% penicillin and streptomycin. Cells were grown in the presence of 1 mM VPA, 5 raM VPA or in the absence of VPA for three days.
[00135] Quantitative RT-PCR. Expression of Oct-4 and Nanog were determined by real-time RT-PCR for each culture condition (0 mM VPA, 1 mM VPA, and 5 mM VPA). Briefly, total RNA was prepared from cultures using Trizol Reagent (Life Technologies, Gaithersburg, MD) and RNeasy Mini kit (Qiagen; Valencia, CA) with DNase I digestion according to manufacturer's protocol. Total RNA (1 μg) from each sample was subjected to oligo(dT)-primed reverse transcription (Invitrogen; Carlsbad, CA). Real-time PCR reactions will be performed with PCR master mix on a 7300 real-time PCR system (Applied Biosystems; Foster City, CA). For each sample, 1 μl of diluted cDNA (1 : 10) will be added as template in PCR reactions. The expression level of Oct-4 and Nanog was normalized to GAPD.
[00136] Embryonic Taqman Low Density Array Analysis. Expression levels of several genes that contribute to a cell being pluripotentail ("sternness genes") were determined using the Human Embryonic Taqman Low Density Array Analysis (TLDA). Several sternness genes were analyzed: GABRB3, LEFTB, NR6A1, PODXL, and PTEN. In addition, the expression level of the DNA methyl transferase DNMT3B was determined. The Applied Biosystems Human Embryonic TLDA, which contains 90 embryonic stem cell and developmental genes and 6 endogenous control genes, was used for quantitative real time RT-PCR to quantify relative expression levels (Applied Biosytems, Foster City, CA). Briefly, following reverse- transcription of RNA using the ABI High Capacity cDNA Reverse Transcription Kit (ABI; Foster City, CA), 150 ng sample cDNA in 50 μl nuclease-free water + 50 μl ABI Universal Taqman 2X PCR Master Mix was pipetted into each port of the TLDA microfluidic card, and analyzed on the ABI 7900HT Fast Real Time PCR System. The ΔΔCT method was used to calculate relative quantities (fold change) in gene expression levels in treated cells relative to untreated control cells. The treated cells may also be compared to federally-approved human embryonic stem cells. [00137] Bisulfite Sequencing. Bisulfite sequencing is the use of bisulfite treatment of DNA to determine the pattern of methylation. Bisulfite sequencing is based on the fact that treatment of DNA with bisulfite converts cytosine residues to uracil, but leaves 5-methylcytosine residues unaffected. Bisulfite treatment thus introduces specific changes in the DNA sequence that depend on the methylation status of individual cytosine residues, yielding very high-resolution information about the methylation status of a segment of DNA.
[00138] Methylation of pluripotent gene promoters was analyzed by bisulfite sequencing. Briefly, DNA was purified by phenolchloroform-isoamylalcohol extraction. Bisulfite conversion was performed using the EZ DNA Methylation kit following the manufacturer's protocol (Zymo Research; Orange, CA). The conversion rate of all cytosines in non-CpG dinucleotides to uracils was 100%. Converted DNA was amplified by PCR using primers for human Oct3/4, Nanog, and SOX2. PCR products were cloned into E. coli by TOPO TA cloning kit (Invitrogen; Carlsbad, CA). Ten clones of each sample were verified by sequencing with SP6 and T7 primers. The global methylation percentage for each promoter of interest and the number of methylated cytosines for a given CpG was compared among cell populations.
[00139] Results
[00140] As shown in FIG. 1, the expression of Oct4 was up-regulated (~2.7-fold; p<0.01) in primary human lung cells treated with 5 mM VPA compared to control cells (MC). These results demonstrate that an HDAC inhibitor can lead to the induction or increased expression of a gene that contributes to a cell being pluripotent. [00141] The expression level of several "stemness"genes also was analyzed using cells grown in 5 mM VPA for three days. As shown in FIG. 2, Embryonic Taqman Low Density Array analysis revealed up-regulation of the following sternness genes: GABRB3 (p<0.05); LEFTB (p<0.05); NR6A1 ((p<0.03); PODXL (p<0.05); PTEN (p<0.01) (n = three replicates per group). In addition, the DNA methyltransferase, DNMT3B, was down-regulated. Several other sternness-related genes that were not detected in control cells were induced in the VPA-treated cells, including FOXD3, NR5A2, TERT, LEFR, SFRP2, TFCP2L1, LIN28, SOX2 and XIST. [00142] The first exon of the Oct-4 gene was analyzed by bisulfite sequencing. Bisulfite sequencing revealed methylated cytosines in untreated (-) and treated (+) cells upstream from Oct4 (3F-3R) (see FIG. 3). In addition, two cytosines in CpG dinucleotides in the promoter/first exon region of Oct4 in treated cells were demethylated (see FIG. 3). These patterns were consistent among several clones (data not shown).
[00143] These results demonstrate that an HDAC inhibitor can induce the expression of genes that contribute to a cell being pluripotent or multipotent, can reduce the expression of a DNA methyl transferase, and de-methylate cytosines in DNA. Additionally, the HDAC inhibitor can lead to demethylation of cytosines in promoter regions of genes that contribute to a cell being pluripotent or multipotent.
[00144] Example 2:
[00145] The effect of HDAC7 shRNA lentiviral infection on the level of mRNA expression on Oct-4., Nanog, and Sox 2 was tested. In addition, in a separate set of experiments, the effect of HDACl 1 shRNA lentiviral infection on the level of mRNA expression on Oct-4., Nanog, and Sox 2 also was tested. Three types of human dermal fibroblasts were used: adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf). [00146] Methods;
[00147] Human dermal fibroblasts (HDFa, HDFn, and HDFf) were infected with shRNA lentivirus to interfere with HDAC7. In a separate set of experiments, human dermal fibroblasts (HDFa, HDFn, and HDFf) were infected with shRNA lentivirus to interfere with HDACl 1. RNA was isolated from HDFs (including puromycin selection) and applied to RT-PCR to analyze expression of target genes, e.g., Oct-4, Nanog, Sox2, various HDACs and various SIRT genes. The shRNA construct included puromycin (antibiotic) resistance as a way to select cells that have been successfully transfected with the shRNA. After transfection, puromycin was added to the culture and cells that were not resistant (therefore not transfected) died, thereby leaving only transfected cells remaining in the culture. [00148] Cell culture. Human dermal fibroblasts were purchased from Cell
Applications (San Diego, CA), and were maintained at 37°C in 95% humidity and 5%
CO2 in Fibroblast growth medium (Cell Applications, San Diego, CA).
[00149] Lentiviral Infection. Human dermal fibroblasts were infected with a shRNA construct. The shRNA construct was obtained from Dharmacon. The shRNA construct directed toward directed toward HDAC7a had the following sequence:
[00150] SEQ ID NO. 1 : GCTTTCAGGATAGTCGTGA
[00151] An shRNA construct with the following sequence was directed against
HDACI l:
[00152] SEQ ID NO. 2: AGCGAGACTTCATGGACGA
[00153] In addition, an shRNA construct with the following sequence was directed against HDACI l :
[00154] SEQ ID. NO.3: TGGTGGT ATACAATGCAGG
[00155] The human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions. HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
Canada) on matrigel (BD Biosciences, San Jose CA). In these sets of experiments, cells were infected with a shRNA construct directed toward either HDAC7, or
HDACI l.
[00156] Quantitative RT-PCR. Expression of Oct-3/4 and Nanog was determined by real-time RT-PCR. Briefly, total RNA was prepared from cultures using Trizol
Reagent (Life Technologies, Gaithersburg, MD) and RNeasy Mini kit (Qiagen;
Valencia, CA) with DNase I digestion according to manufacturer's protocol. Total
RNA (1 μg) from each sample was subjected to oligo(dT)-primed reverse transcription
(Invitrogen; Carlsbad, CA). Real-time PCR reactions will be performed with PCR master mix on a 7300 real-time PCR system (Applied Biosystems; Foster City, CA).
For each sample, 1 μl of diluted cDNA (1: 10) will be added as template in PCR reactions. The expression level of Oct-3/4 and Nanog was normalized to glyceraldehyde 3-phosphate-dehydrogenase (GAPD).
[00157] Results;
[00158] The effects of HDAC7 and HDAC 11 shRNA lentiviral infection on the mRNA level of the gene Nanog are shown in FIG. 4A (HDFa), FIG. 4B (HDFn) and FIG. 4C (HDFf). For all three cell types, both HDAC7 and HDACl 1 knockdown increased the level of mRNA for the gene Nanog, both in the presence and absence of puromycin (shown for adult and neonatal human dermal fibroblasts). For the cell types HDFa and HDFn, expression of Nanog increased at least six-fold over time. The increase in the level of Nanog mRNA was seen with and without puromycin selection. As reported in FIG. 4A, interference with HDAC7 resulted in a rapid increase in mRNA expression of Nanog as compared to interference with HDACl 1. However, with additional time, the increase in the level of mRNA of the gene Nanog appeared to be equal, regardless of whether HDAC7 or HDACl 1 was interfered. An increase in the level of mRNA for the gene Nanog was seen in HDFf, but not as robustly as observed for HDFa and HDFn.
[00159] The effects of HDAC7 and HDAC 11 shRNA lentiviral infection on the mRNA level of the gene Oct-4 are shown in FIG. 5A (HDFa), FIG. 5B (HDFn) and FIG. 5C (HDFf). Both HDAC7 and HDACl 1 knockdown increased the level of mRNA for the gene Nanog in the cell types HDFa and HDFn. The increase in expression of Oct-4 was observed both in the presence and absence of puromycin (FIG. 5A and FIG. 5B). A more modest increase in the level of mRNA for the gene Oct-4 was observed as compared to the gene Nanog.
[00160] FIG.6 reports the effect of HDAC7 and HDAC 1 1 shRNA lentiviral infection on the mRNA level of Sox-2 in fetal human dermal fibroblasts. No induction in the level of mRNA for the Sox-2 gene was observed.
[00161] FIG. 7 reports the effects of HDAC7 shRNA lentiviral infection on the level of mRNA expression of various HDAC genes and SIRT genes. As shown in FIG. 7, the expression of HDAC 9, HDAC5 and HDACl 1 mRNA was inducted three days after HDAC7 shRNA infection. The level of HDAC7 mRNA was reduced about 50% of basal level around three days after lentiviral infection.
[00162] The inhibition of one HDAC, in this case HDAC7, led to an increase in the expression of several other HDAC genes. HDACs are closely related, and have likely evolved to have redundant or at least similar functions. If one family member is inhibited, the expression of other family members may be increased to compensate for the inhibited member. HDACs play a crucial function and therefore, redundant and/or compensatory pathways may have evolved. One mechanism to reprogram a cell may be to simultaneously or sequentially target multiple family members to account for the redundant and/or compensatory pathways. Another mechanism to reprogram a cell may be to simultaneously or sequentially target inhibitory proteins in the same family or to target inhibitory proteins in different families of regulatory proteins.
[00163] Example 4:
[00164] The effect of HDAC7 and HDACl 1 shRNA lentiviral infection on the level of mRNA expression on Oct-4, Nanog, and Sox 2 was tested. In the same experiment,
HDAC7 and HDACl 1 were interfered with and the effect on the expression of various genes determined. Three types of human dermal fibroblasts were used: adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf).
[00165] Methods;
[00166] Human dermal fibroblasts (HDFa, HDFn, and HDFf) were infected with shRNA lentivirus to interfere with HDAC7 and HDACl 1. RNA was isolated from
HDFs (including puromycin selection) and applied to RT-PCR to analyze expression of target genes, e.g., Oct-4, Nanog, Sox2, various HDACs and various SIRT genes.
The shRNA construct included puromycin (antibiotic) resistance as a way to select cells that have been successfully transfected with the shRNA. After transfection, puromycin was added to the culture and cells that were not resistant (therefore not transfected) died, thereby leaving only transfected cells remaining in the culture.
[00167] Cell culture. Human dermal fibroblasts were purchased from Cell
Applications (San Diego, CA), and were maintained at 37°C in 95% humidity and 5%
CO2 in Fibroblast growth medium (Cell Applications, San Diego, CA).
[00168] Lentiviral Infection. Human dermal fibroblasts were infected with a shRNA construct. The shRNA construct was obtained from Dharmacon. The shRNA construct directed toward directed toward HDAC7a had the following sequence:
[00169] SEQ ID NO. 1 : GCTTTCAGGATAGTCGTGA
[00170] An shRNA construct with the following sequence was directed against
HDACI l:
[00171] SEQ ID NO. 2: AGCGAGACTTCATGGACGA [00172] In addition, an shRNA construct with the following sequence was directed against HDACI l :
[00173] SEQ ID. NO.3: TGGTGGTATACAATGCAGG
[00174] The human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions. HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
Canada) on matrigel (BD Biosciences, San Jose CA).
[00175] Quantitative RT-PCR. Expression of Oct-3/4 and Nanog was determined by real-time RT-PCR. Briefly, total RNA was prepared from cultures using Trizol
Reagent (Life Technologies, Gaithersburg, MD) and RNeasy Mini kit (Qiagen;
Valencia, CA) with DNase I digestion according to manufacturer's protocol. Total
RNA (1 μg) from each sample was subjected to oligo(dT)-primed reverse transcription
(Invitrogen; Carlsbad, CA). Real-time PCR reactions will be performed with PCR master mix on a 7300 real-time PCR system (Applied Biosystems; Foster City, CA).
For each sample, 1 μl of diluted cDNA (1 : 10) will be added as template in PCR reactions. The expression level of Oct-3/4, Nanog and Sox-2 was normalized to glyceraldehyde 3-phosphate-dehydrogenase (GAPD).
[00176] Results:
[00177] As reported in FIG. 8, Nanog expression increased by double knockdown of HDAC7 and HDACl 1 for both cell types HDFf and HDFn, both in the presence and absence of puromycin. Nanog expression increased rapidly in the cell type HDFf and a consistent response was observed through day five. A modest effect was observed in cell type HDFa.
[00178] FIG. 9 reports the effect on the mRNA expression of Oct-4 during dual or simultaneous HDAC7 and HDACl 1 shRNA interference. The increase in Oct-4 expression was observed both in the presence and absence of puromycin. A robust effect was observed for the cell type HDFn, and the mRNA expression was increased for Oct-4 as compared to a single knockdown of either HDAC7 or HDACl 1.
[00179] As reported in FIG. 10, Sox-2 expression occurred consistently in fetal human dermal fibroblasts. The expression of Sox-2 was maintained by double knockdown of HDAC7 and HDAC 11. [00180] FIG. 11 reports the effects on the mRNA expression of various HDAC genes during dual HDAC7 and HDACl 1 shRNA interference in adult human dermal fibroblasts. A robust increase in the expression of HDAC9 was observed. The expression of HDAC5 also was increased. Modest effects were observed on other genes (see FIG. 11).
[00181] FIG. 12 reports the effects on the mRNA expression of various HDAC genes during dual HDAC7 and HDACl 1 shRNA interference in fetal human dermal fibroblasts. A robust increase in the expression of HDAC9 was observed at day seven with puromyocin selection. The expression of various other HDAC genes was decreased at day seven with puromyocin selection (see FIG. 12). [00182] FIG. 13 reports the effects on the mRNA expression of various HDAC genes during dual HDAC7 and HDAC 1 1 shRNA interference in neonatal human dermal fibroblasts. A robust increase in the expression of HDAC9 was observed at day without puromyocin selection and at day five with puromyocin selection. The expression of HDAC5 also was increased. Modest effects were observed on other genes (see FIG. 13).
[00183] These results demonstrate that a shRNA construct can be used to inhibit the expression of genes that code for an HDAC, and can induce expression of pluripotent genes, such as Oct-4 and Nanog, which are two genes involved in reprogramming a cell. Further, these results demonstrate that inhibition of HDACs can play an essential role in restoring differentiation potential to ac cell. The methods of the invention can be used to inhibit any HDAC or an HDAC related protein, either in structure or function.
[00184] To account for any compensatory pathway, redundant pathways, or compensatory and redundant pathways, more than one HDAC or any other protein involved in silencing of pluripotency genes may be inhibited. One or more proteins from the same family of inhibitory proteins, or two or more proteins from two different families of inhibitory proteins may be inhibited. One efficient mechanism for reprogramming a cell may to inhibit multiple proteins within the compensatory, redundant or compensatory and redundant pathways. Proteins that function within this inhibitory pathway may be inhibited by shRNA, HDAC inhibitors, small molecule inhibitors or any combination of the above-recited. [00185] Example 5:
[00186] The effect of HDAC7 shRNA lentiviral infection on the expression of
HDACl 1, was tested. Three types of human dermal fibroblasts were used: adult human dermal fibroblasts (HDFa), neonatal human dermal fibroblasts (HDFn), and fetal human dermal fibroblasts (HDFf)-
[00187] Methods
[00188] Cell culture. Human dermal fibroblasts were purchased from Cell
Applications (San Diego, CA), and were maintained at 370C in 95% humidity and 5%
CO2 in Fibroblast growth medium (Cell Applications, San Diego, CA).
[00189] Lentiviral Infection. Human dermal fibroblasts were infected with a shRNA construct. The shRNA construct was obtained from Dharmacon. The shRNA construct directed toward HDAC7a had the following sequence:
[00190] SEQ ID NO. 1 : GCTTTCAGGAT AGTCGTGA
[00191] The human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions. HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
Canada) on matrigel (BD Biosciences, San Jose CA).
[00192] Quantitative RT-PCR. Expression of HDAC7a and HDAC 1 1 was determined by real-time RT-PCR. Briefly, total RNA was prepared from cultures using Trizol Reagent (Life Technologies, Gaithersburg, MD) and RNeasy Mini kit
(Qiagen; Valencia, CA) with DNase I digestion according to manufacturer's protocol.
Total RNA (1 μg) from each sample was subjected to oligo(dT)-primed reverse transcription (Invitrogen; Carlsbad, CA). Real-time PCR reactions will be performed with PCR master mix on a 7300 real-time PCR system (Applied Biosystems; Foster
City, CA). For each sample, 1 μl of diluted cDNA (1: 10) will be added as template in
PCR reactions. The expression level of HDAC7a and HDACl 1 was normalized to glyceraldehyde 3-phosphate-dehydrogenase (GAPD).
[00193] Results
[00194] The expression of HDACl 1 was increased, while the expression of
HDAC7a was decreased, in fetal human dermal fibroblasts infected with HDAC7a shRNA (FIG. 14A). Similar results were obtained with neonatal human dermal fibroblasts (FIG. 14B) and fetal human dermal fibroblasts (FIG. 14C). The increase in expression was observed both in the presence and absence of puromycin. HDACl 1 expression was up-regulated in a compensatory fashion in all three cell types tested. Inhibiting the expression of a gene that codes for a regulatory protein, which is involved in decreasing expression of a pluripotent gene, may lead to an increase in expression of other genes coding for a regulatory protein. Multiple agents targeted to a single family of regulatory proteins or multiple families of regulatory proteins may be an efficient means to reprogram a cell. The agents include but are not limited to small molecule inhibitors and shRNA constructs.
[00195] Example 6
[00196] Cells infected with lentivirus shRNA directed to HDAC7, HDACl 1 or
DNMTl were stained and visualized for expression of pluripotent genes. Protein expression of Oct-4 and Sox-2 was analyzed in this example, but one of ordinary skill in the art will understand the methods of the invention can be used to increase expression of any gene involved in reprogramming or restoring differentiation potential to a cell.
[00197] Methods
[00198] Cell culture. Fetal human dermal fibroblasts were purchased from Cell
Applications (San Diego, CA), and were maintained at 370C in 95% humidity and 5%
CO2 in Fibroblast growth medium (Cell Applications, San Diego, CA).
[00199] Lentiviral Infection. Fetal human dermal fibroblasts were infected with one of the following compositions: (1) shRNA lentivirus directed to DNMTl ; (2) shRNA lentivirus directed toward HDAC7; (3) shRNA lentivirus directed toward
DNMTl and HDAC7; and (4) shRNA lentivirus directed toward HDAC7a and
HDACI l. The shRNA construct was obtained from Dharmacon. The shRNA construct directed toward HDAC7a had the following sequence:
[00200] SEQ ID NO. 1 : GCTTTCAGGATAGTCGTGA
[00201] An shRNA construct with the following sequence was directed against
HDACI l:
[00202] SEQ ID NO. 2: AGCGAGACTTC ATGG ACGA [00203] In addition, an shRNA construct with the following sequence was directed against HDACI l :
[00204] SEQ ID. NO.3: TGGTGGT ATACAATGCAGG
[00205] The shRNA construct directed toward DNMTl had the following sequence:
[00206] SEQ ID NO.4: GTCTACCAGATCTTCGATA
[00207] The human dermal fibroblasts were infected with the shRNA following the manufacturer's instructions. HDF were cultured with an without puromycin selection and hES culture conditions (mTeSR Medium, Stem Cell Technology, Vancouver, BC,
Canada) on matrigel (BD Biosciences, San Jose CA).
[00208] Immunohistochemistry. For immunohistochemistry, target shRNA- infected and control cells were grown on chambered slides (LabTek, Napersville, IL).
Cells were then be fixed with 4% paraformaldehyde, and incubated with a specific antibody directed against pluripotency marker Oct3/4 (Abeam, Cambridge, MA) following the manufacturer's protocol. Staining of Oct3/4 was visualized as a red color. The nucleus was visualized with DAPI staining (Vectorshield), which appeared as a blue color.
[00209] Results
[00210] Oct-4 protein expression was increased in fetal human dermal fibroblasts
(HDFf) by shRNA interference. FIG. 15A is a photograph of HDFf without infection
(negative control). FIG. 15G is a photograph of human embryonic stem cells (positive control). In the negative control cells, little expression of Oct-4 protein was detected.
FIG. 15B is a photograph of HDFf cells infected with shRNA directed toward
DNMTl. Oct-4 protein expression is clearly increased when cells are exposed to
DNMTl shRNA. HDFf cells infected with HDAC7 shRNA show minimal detection of Oct-4 protein (FIG. 15C). This may be due to the processing of this particular sample.
[00211] Cells infected with DNMTl and HDAC7 shRNA showed a dramatic increase in the expression of Oct-4 protein (FIG. 15D). The cells treated with both
DNMTl and HDAC7 shRNA produce an expression pattern very similar to human embryonic stem cells (Invitrogen, Carlsbad, CA) (FIG. 15E). These data corroborate data presented herein that an increase in Oct-4 gene expression leads to an increase in
Oct-4 protein expression. DNMT and HDACl 1 have distinct functions with regard to regulation of activation of transcription and chromatin remodeling. The inhibition of members from two separate regulatory groups resulted in a dramatic increase in the expression of Oct-4. Oct-4 protein expression was also increased in cells infected with DNMTl and HDACl 1 (FIG. 15E). Inhibition of DNMTl and multiple HDACs resulted in increase in expression of Oct-4 protein.
[00212] There was no detectable increase in expression of Oct-4 in cells infected with HDAC7 and HDACl 1 shRNA (FIG. 15F). This may be due a limitation of the experimental system. Alternatively, this result may suggest for optimal increase in expression of pluripotent genes, multiple pathways should be inhibited. Inhibiting the expression of genes that code for proteins that function in distinct regulatory complexes may result in higher expression levels of pluripotent genes. Any member of any regulatory complex may be inhibited.
[00213] Sox-2 protein expression was increased in fetal human dermal fibroblasts (HDFf) by shRNA interference. FIG. 16A is a photograph of HDFf without infection (negative control). FIG. 16G is a photograph of human embryonic stem cells (FIG. 16G). In the negative control cells, little expression of Sox-2 protein was detected. FIG. 16B is a photograph of HDFf cells infected with shRNA directed toward DNMTl . Nuclear staining was visible, however only a modest amount of Sox-2 protein was detected. HDFf cells infected with HDAC7 and DNMTl shRNA showed minimal detection of Sox-2protein (FIG. 16C). This may be due to the processing of this particular sample.
[00214] Cells infected with DNMTl and HDACl 1 shRNA showed a dramatic increase in the expression of Sox-2 protein (FIG. 16D). The inhibition of members from two separate regulatory groups resulted in a dramatic increase in the expression of Sox-2. Cells infected with HDAC7 shRNA showed minimal protein expression of Sox-2 (FIG. 16E). Sox-2 protein expression was also increased in cells infected with HDAC7 and HDACl 1 (HG. 16F). Inhibition of DNMTl and multiple HDACs resulted in increase in expression of Sox-2 protein.
[00215] These results demonstrate that the inhibition of histone deacetylases and DNA methyl transferases increased the expression of pluripotent genes involved in reprogramming a cell. Two distinct shRNA constructs were targeted to two separate regulatory proteins, which resulted in a dramatic increase in expression of the Oct-4 and Sox-2 protein. Inhibiting more than one regulatory protein involved in inhibiting or repressing transcription of pluripotent genes may be an efficient mechanism to reprogram a cell and restore differentiation potential to a cell. [00216] The inhibition of histone deacetylases and related family members can be used to increase the expression of pluripotent genes, and can be used to reprogram a differentiated cell. These reprogramming methods are independent of eggs, embryos or embryonic stem cells. Furthermore, these methods do not rely on viral vectors, which can have harmful effects. These methods are also independent of oncogenes, such as c-myc and Klf4.
[00217] In addition, the methods of the present invention can be used to reprogram a differentiated cell in the absence of somatic cell nuclear transfer (SCNT). SCNT is very inefficient and has posed a significant limitation on the field of reprogramming. The present methods alleviate the need for SCNT.
[00218] The present methods have demonstrated an increase in expression of the endogenous pluripotent genes and proteins, as opposed to measuring effects on an artificial vector with a strong reporter element. An artificial vector does not have the same chromatin structure as the endogenous gene, nor does it have other genes, and promoter elements to create the environment of the genome. An artificial vector does not have many of the natural elements needed to recapitulate the environment of the natural genome. The results presented herein represent effects obtained from treating human cells, and measuring the effects on the endogenous gene. [00219] Finally, the data presented herein demonstrate that inhibiting or altering the function of histone deacetylases is one step involved in reprogramming a differentiated cell, and restoring differentiation potential.
[00220] Although specific embodiments have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that any arrangement that is calculated to achieve the same purpose may be substituted for the specific embodiments shown. This application is intended to cover any adaptations or variations that operate according to the principles of the invention as described. Therefore, it is intended that this invention be limited only by the claims and the equivalents thereof. The disclosures of patents, references and publications cited in the application are incorporated by reference herein.

Claims

WHAT IS CLAIMED IS:
1. A method for reprogramming a cell comprising: exposing a population of cells to an agent that inhibits activity, expression, or activity and expression of a histone deacetylase; inducing expression of a pluripotent gene; selecting a cell that express a cell surface marker indicative of a pluripotent cell, and expanding said selected cell to produce a population of cells, wherein differentiation potential has been restored to said cell.
2. The method of Claim 1, wherein said selecting a cell further comprises comparing phenotypes of the cell prior to and after exposure to said agent, and identifying a cell with a phenotype consistent with a pluripotent cell.
3. The method of Claim 1, wherein said selecting a cell further comprises using an antibody directed to protein coded for by a pluripotent gene or a cell-surface marker.
4. The method of Claim 3, wherein said cell surface marker is selected from the group consisting of: SSE A3, SSE A4, Tra-1-60, and Tra-1-81.
5. The method of Claim 1 further comprising: prior to expanding said cell, comparing chromatin structure of a pluripotent gene of said cell that exist prior to exposure to said agent to the chromatin structure obtained after exposure to said agent.
6. The method of Claim 5, wherein comparing chromatin structure comprises comparing acetylation state of histones.
7. The method of Claim 5, wherein said pluripotent gene is selected from the group consisting of: Oct-4, Sox-2 and Nanog.
8. The method of Claim 1, wherein said agent is selected from the group consisting of: a small molecule inhibitor, a nucleic acid sequence, and a shRNA construct.
9. The method of Claim 8, wherein said histone deacetylase is selected from the group consisting of: HDACl, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC6, HDAC7A, HDAC9, HDAClO, HDACI l, SIRTl, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.
10. A method for reprogramming a cell comprising: exposing a cell to a first agent that inhibits that activity, expression, or expression and activity of a HDAC; exposing said cell to a second agent that inhibits the activity, expression or expression and activity of a second regulatory protein, wherein said second regulatory protein has a distinct function from the HDAC, inducing expression of a pluripotent gene, and selecting a cell, wherein differentiation potential has been restored to said cell.
11. The method of Claim 10, wherein said cell is exposed to said first and second agent simultaneously.
12. The method of Claim 10, wherein selecting a cell comprises isolating a cell using an antibody directed to a protein coded for by a pluripotent gene or a cell-surface marker.
13. The method of Claim 12, wherein said cell surface marker is selected from the group consisting of: SSEA3, SSEA4, Tra-1-60, and Tra-1-81.
14. The method of Claim 10, wherein selecting said cell comprises comparing phenotypes of the cell prior to and after exposure to said first and second agents.
15. The method of Claim 10, wherein said first and second agents are selected from the group consisting of: a small molecule inhibitor, a nucleic acid sequence, and a shRNA construct.
16. The method of Claim 10, wherein said second regulatory protein is selected from the group consisting of: histone deacetylase, a histone acetyltransferase, a lysine methyltransferase, a histone methyltransferase, a histone demethylase, a lysine demethylase, a sirtuin, and a sirtuin activator.
17. An enriched population of reprogrammed cells produced according to a method comprising the steps of: exposing a population of cells to an agent that inhibits activity, expression of activity and expression of a histone deacetylase; inducing expression of a pluripotent gene; selecting a cell that express a cell surface marker indicative of a pluripotent cell, and expanding said selected cell to produce a population of cells, wherein differentiation potential has been restored to said cell
18. The enriched population of reprogrammed cells of Claim 17, wherein the reprogrammed cell expresses a cell surface marker selected from the group consisting of: SSEA3, SSEA4, Tra-1-60, and Tra-1-81.
19. The enriched population of reprogrammed cells of Claim 17, wherein the pluripotent gene is selected from the group consisting of: Oct-4, Nanog, and Sox-2.
20. The enriched population of reprogrammed cells of Claim 17, wherein said reprogrammed cells account for at least 60% of the population.
PCT/US2009/002163 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator WO2009126251A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2011503981A JP2011516076A (en) 2008-04-07 2009-04-07 Cell reprogramming by inducing pluripotency genes through the use of HDAC modifiers
EP09729724A EP2274424A4 (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
CN2009801207529A CN102083981A (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator
AU2009234424A AU2009234424A1 (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US4306608P 2008-04-07 2008-04-07
US4289008P 2008-04-07 2008-04-07
US4299508P 2008-04-07 2008-04-07
US61/042,995 2008-04-07
US61/043,066 2008-04-07
US61/042,890 2008-04-07
US11397108P 2008-11-12 2008-11-12
US61/113,971 2008-11-12

Publications (2)

Publication Number Publication Date
WO2009126251A2 true WO2009126251A2 (en) 2009-10-15
WO2009126251A3 WO2009126251A3 (en) 2010-03-18

Family

ID=41162444

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2009/002163 WO2009126251A2 (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
PCT/US2009/039815 WO2009126655A2 (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator
PCT/US2009/002161 WO2009126250A2 (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through rna interference

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2009/039815 WO2009126655A2 (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator
PCT/US2009/002161 WO2009126250A2 (en) 2008-04-07 2009-04-07 Reprogramming a cell by inducing a pluripotent gene through rna interference

Country Status (7)

Country Link
US (1) US20090253203A1 (en)
EP (3) EP2276838A4 (en)
JP (3) JP2011516076A (en)
KR (3) KR20110007607A (en)
CN (3) CN102083982A (en)
AU (3) AU2009233845A1 (en)
WO (3) WO2009126251A2 (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013058403A1 (en) 2011-10-21 2013-04-25 国立大学法人京都大学 Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow
WO2013077423A1 (en) 2011-11-25 2013-05-30 国立大学法人京都大学 Method for culturing pluripotent stem cell
WO2014123242A1 (en) 2013-02-08 2014-08-14 国立大学法人京都大学 Production methods for megakaryocytes and platelets
WO2014136581A1 (en) 2013-03-06 2014-09-12 国立大学法人京都大学 Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
WO2014148646A1 (en) 2013-03-21 2014-09-25 国立大学法人京都大学 Pluripotent stem cell for neuronal differentiation induction
WO2014157257A1 (en) 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 Cell sorting method
WO2014168264A1 (en) 2013-04-12 2014-10-16 国立大学法人京都大学 Method for inducing alveolar epithelium progenitor cells
WO2014185358A1 (en) 2013-05-14 2014-11-20 国立大学法人京都大学 Efficient myocardial cell induction method
WO2014192909A1 (en) 2013-05-31 2014-12-04 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 Layered cell sheet incorporating hydrogel
WO2014200115A1 (en) 2013-06-11 2014-12-18 国立大学法人京都大学 Method for producing renal precursor cells, and drug containing renal precursor cells
WO2015020113A1 (en) 2013-08-07 2015-02-12 国立大学法人京都大学 Method for producing pancreatic hormone-producing cell
WO2015034012A1 (en) 2013-09-05 2015-03-12 国立大学法人京都大学 New method for inducing dopamine-producing neural precursor cells
WO2015064754A1 (en) 2013-11-01 2015-05-07 国立大学法人京都大学 Novel chondrocyte induction method
EP3081638A1 (en) 2015-04-16 2016-10-19 Kyoto University Method for producing pseudo-islets
WO2017183736A1 (en) 2016-04-22 2017-10-26 国立大学法人京都大学 Method for producing dopamine-producing neural precursor cells
EP3305899A1 (en) 2011-07-25 2018-04-11 Kyoto University Method for screening induced pluripotent stem cells
WO2018124118A1 (en) 2016-12-27 2018-07-05 住友化学株式会社 Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells
WO2018135646A1 (en) 2017-01-20 2018-07-26 国立大学法人京都大学 METHOD FOR PRODUCING CD8α+β+ CYTOTOXIC T CELLS
WO2018139548A1 (en) 2017-01-26 2018-08-02 国立大学法人大阪大学 Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells
WO2018168829A1 (en) 2017-03-14 2018-09-20 国立大学法人京都大学 Method for producing helper t cells from pluripotent stem cells
WO2018216743A1 (en) 2017-05-25 2018-11-29 国立大学法人京都大学 Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell
WO2018235583A1 (en) 2017-06-19 2018-12-27 公益財団法人神戸医療産業都市推進機構 Method of predicting differentiation ability of pluripotent stem cells and reagent therefor
WO2019078263A1 (en) 2017-10-17 2019-04-25 国立大学法人京都大学 Method for obtaining artificial neuromuscular junction from pluripotent stem cells
WO2020013315A1 (en) 2018-07-13 2020-01-16 国立大学法人京都大学 METHOD FOR PRODUCING γδ T CELLS
WO2020017575A1 (en) 2018-07-19 2020-01-23 国立大学法人京都大学 Plate-shaped cartilage derived from pluripotent stem cells and method for producing plate-shaped cartilage
WO2020022261A1 (en) 2018-07-23 2020-01-30 国立大学法人京都大学 Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
WO2020116606A1 (en) 2018-12-06 2020-06-11 キリンホールディングス株式会社 Production method for t cells or nk cells, medium for culturing t cells or nk cells, method for culturing t cells or nk cells, method for maintaining undifferentiated state of undifferentiated t cells, and growth-accelerating agent for t cells or nk cells
WO2020130147A1 (en) 2018-12-21 2020-06-25 国立大学法人京都大学 Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
WO2020138371A1 (en) 2018-12-26 2020-07-02 キリンホールディングス株式会社 Modified tcr and production method therefor
US10711249B2 (en) 2014-12-26 2020-07-14 Kyoto University Method for inducing hepatocytes
WO2020230832A1 (en) 2019-05-15 2020-11-19 味の素株式会社 Method for purifying neural crest cells or corneal epithelial cells
WO2020235319A1 (en) 2019-05-20 2020-11-26 味の素株式会社 Expansion culture method for cartilage or bone precursor cells
WO2021117886A1 (en) 2019-12-12 2021-06-17 国立大学法人千葉大学 Freeze-dried preparation containing megakaryocytes and platelets
WO2021174004A1 (en) 2020-02-28 2021-09-02 Millennium Pharmaceuticals, Inc. Method for producing natural killer cells from pluripotent stem cells
WO2021256522A1 (en) 2020-06-17 2021-12-23 国立大学法人京都大学 Chimeric antigen receptor-expressing immunocompetent cells
EP3929302A1 (en) 2014-07-14 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Method for identifying epitope on protein
WO2022014604A1 (en) 2020-07-13 2022-01-20 国立大学法人京都大学 Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
WO2022019152A1 (en) 2020-07-20 2022-01-27 学校法人 愛知医科大学 Composition for undifferentiated maintenance culture of pluripotent cells, medium for undifferentiated maintenance culture of pluripotent cells, maintenance culture method in undifferentiated state of pluripotent cells, and method for producing pluripotent cells
WO2022039279A1 (en) 2020-08-18 2022-02-24 国立大学法人京都大学 Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells
US11401504B2 (en) 2016-04-15 2022-08-02 Kyoto University Method for inducing antigen specific CD8 positive T cells
WO2022196714A1 (en) 2021-03-17 2022-09-22 アステラス製薬株式会社 Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein
WO2022230977A1 (en) 2021-04-30 2022-11-03 国立研究開発法人理化学研究所 Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates
WO2022255489A1 (en) 2021-06-04 2022-12-08 キリンホールディングス株式会社 Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition
WO2022259721A1 (en) 2021-06-10 2022-12-15 味の素株式会社 Method for producing mesenchymal stem cells
WO2022264033A1 (en) 2021-06-15 2022-12-22 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
WO2023286834A1 (en) 2021-07-15 2023-01-19 アステラス製薬株式会社 Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level
WO2023286832A1 (en) 2021-07-15 2023-01-19 アステラス製薬株式会社 Pericyte-like cells expressing vascular endothelial growth factor (vegf) at high level
WO2023017848A1 (en) 2021-08-11 2023-02-16 国立大学法人京都大学 Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells
WO2023085356A1 (en) 2021-11-11 2023-05-19 株式会社ヘリオス Gene-modified pluripotent stem cell, immunocompetent cell derived therefrom, method for producing said cells, and use thereof
WO2023153464A1 (en) 2022-02-09 2023-08-17 住友ファーマ株式会社 Method for assessing differentiation potential of cells in culture broth in differentiation of pluripotent stem cells into neural cells of midbrain floor plate region
WO2023210713A1 (en) 2022-04-27 2023-11-02 国立大学法人京都大学 Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration
WO2023238932A1 (en) 2022-06-10 2023-12-14 国立大学法人京都大学 Detection method and detection reagent for undifferentiated pluripotent stem cells
US12241089B2 (en) 2014-07-18 2025-03-04 Kyoto University Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
KR101874463B1 (en) * 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. Methods for reprogramming cells and uses thereof
IN2012DN05181A (en) 2009-11-12 2015-10-23 Vbi Technologies Llc
US20130059385A1 (en) * 2010-03-02 2013-03-07 The Scripps Research Institute Methods of generating pluripotent stem cells
US9517250B2 (en) 2010-04-28 2016-12-13 The J. David Gladstone Institutes Methods for generating cardiomyocytes
WO2012007725A2 (en) 2010-07-16 2012-01-19 Plasticell Ltd Method of reprogramming a cell
US8835400B2 (en) 2010-10-08 2014-09-16 Mina Therapeutics Limited RNA molecules that upregulate insulin production
JP6298405B2 (en) 2011-08-30 2018-03-20 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ Method for generating cardiomyocytes
CN102417894B (en) * 2011-10-21 2013-06-05 中国科学院广州生物医药与健康研究院 A method for improving the efficiency of inducing pluripotent stem cells
AU2012350353B2 (en) * 2011-12-13 2018-01-04 Unisa Ventures Pty Ltd Method of producing multipotent stem cells
CA3236835A1 (en) 2013-11-22 2015-05-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
CN103751806B (en) * 2014-01-23 2015-10-14 中国人民解放军第三军医大学第一附属医院 Interference SIRT1 expresses the application of reagent in the reagent of preparation suppression liver-cancer stem cell dryness transcription factor expression
US20150297638A1 (en) * 2014-04-17 2015-10-22 Muhammad Ashraf Chemically induced pluripotent stem cells for safe therapeutic applications
KR101647030B1 (en) 2014-11-20 2016-08-09 한국생명공학연구원 Compositions comprising a mitofusin inhibitor for promoting cell reprogramming and the use thereof
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
JP7263005B2 (en) * 2015-10-16 2023-04-24 フェイト セラピューティクス，インコーポレイテッド A platform for the induction and maintenance of ground-state pluripotency
WO2018160028A1 (en) * 2017-03-02 2018-09-07 주식회사 셀라토즈테라퓨틱스 Medium composition for neuron differentiation and method for differentiating somatic cells into neurons using same medium composition
CN108588008A (en) * 2018-04-18 2018-09-28 广西壮族自治区畜牧研究所 A kind of black pig handmade cloning in Debao reconstructs drug and the application of vitro Development of Embryos
WO2020077343A1 (en) * 2018-10-12 2020-04-16 Life Technologies Corporation Hematopoietic stem and progenitor cell expansion system
KR20210137499A (en) * 2019-03-05 2021-11-17 더 스테이트 오브 이스라엘, 미니스트리 오브 애그리컬처 & 루럴 디벨로프먼트, 애그리컬처럴 리서치 오거니제이션, (에이.알.오.), 볼카니 센터 Genome-Editing Birds
CN111979194A (en) * 2019-05-24 2020-11-24 北京大学 Methods of reprogramming cells
CN115135312A (en) * 2019-11-25 2022-09-30 宾州研究基金会 Compositions and methods for converting human glial cells into neurons
CN110951738B (en) * 2019-12-23 2021-10-15 华南农业大学 Expression inhibitor of porcine HDAC2 gene and its application
CN115820544A (en) * 2022-09-25 2023-03-21 上海圣石生物医学科技有限公司 Induced pluripotent stem cell exosome and application thereof in preparing anti-aging preparation
AU2023358188A1 (en) * 2022-10-12 2025-05-29 Beicell Therapeutics Inc. Methods for chemical reprogramming and pluripotent stem cells
GB202308828D0 (en) * 2023-06-13 2023-07-26 Res & Innovation Uk Standardising pluripotent stem cells
KR20250091419A (en) 2023-12-13 2025-06-23 단국대학교 천안캠퍼스 산학협력단 Promotion method for cell reprogramming through cyclic stretching

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4968733A (en) 1988-09-01 1990-11-06 Akzo N.V. Process for producing microporous powders and membranes
US4976859A (en) 1988-09-01 1990-12-11 Akzo N.V. Integral asymmetric polyether-sulfone membrane, process for its production, and use for ultrafiltration and microfiltration
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5284761A (en) 1987-11-17 1994-02-08 Brown University Research Foundation Method of encapsulating cells in a tubular extrudate
WO1995005452A2 (en) 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US6498018B1 (en) 1997-09-05 2002-12-24 Cytotherapeutics, Inc. Cultures of human CNS neural stem cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136709A1 (en) * 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
JP2004248505A (en) * 2001-09-21 2004-09-09 Norio Nakatsuji Undifferentiated fusion cell of somatic cell derived from es cell deficient in part or all of transplantation antigen and method for producing the same
US20050170506A1 (en) * 2002-01-16 2005-08-04 Primegen Biotech Llc Therapeutic reprogramming, hybrid stem cells and maturation
US20090023671A1 (en) * 2005-01-06 2009-01-22 Brashears Sarah J Rnai Agents for Maintenance of Stem Cells
GB0515006D0 (en) * 2005-07-22 2005-08-31 Univ Nottingham Reprogramming
JP4395193B2 (en) * 2005-08-01 2010-01-06 ニューポテンシャル，インコーポレイテッド Production of reprogrammed cells with ability to recover
PT1970446E (en) * 2005-12-13 2011-09-01 Univ Kyoto Nuclear reprogramming factor
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US20090252711A1 (en) * 2006-05-11 2009-10-08 Andrew Craig Boquest Stem Cells And Methods Of Making And Using Stem Cells
MX348010B (en) * 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramming of somatic cells.
SG10201808863UA (en) * 2008-03-17 2018-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5284761A (en) 1987-11-17 1994-02-08 Brown University Research Foundation Method of encapsulating cells in a tubular extrudate
US4968733A (en) 1988-09-01 1990-11-06 Akzo N.V. Process for producing microporous powders and membranes
US4976859A (en) 1988-09-01 1990-12-11 Akzo N.V. Integral asymmetric polyether-sulfone membrane, process for its production, and use for ultrafiltration and microfiltration
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
WO1995005452A2 (en) 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6498018B1 (en) 1997-09-05 2002-12-24 Cytotherapeutics, Inc. Cultures of human CNS neural stem cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1997, JOHN WILEY & SONS
FORTUNEL ET AL., SCIENCE, vol. 302, 2003, pages 393B
IVANOVA ET AL., SCIENCE, vol. 298, 2002, pages 601
RAMALHO-SANTOS ET AL., SCIENCE, vol. 298, 2002, pages 597
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY
See also references of EP2274424A4

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3608423A1 (en) 2011-07-25 2020-02-12 Kyoto University Method for screening induced pluripotent stem cells
EP3305899A1 (en) 2011-07-25 2018-04-11 Kyoto University Method for screening induced pluripotent stem cells
WO2013058403A1 (en) 2011-10-21 2013-04-25 国立大学法人京都大学 Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow
WO2013077423A1 (en) 2011-11-25 2013-05-30 国立大学法人京都大学 Method for culturing pluripotent stem cell
WO2014123242A1 (en) 2013-02-08 2014-08-14 国立大学法人京都大学 Production methods for megakaryocytes and platelets
WO2014136581A1 (en) 2013-03-06 2014-09-12 国立大学法人京都大学 Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
WO2014148646A1 (en) 2013-03-21 2014-09-25 国立大学法人京都大学 Pluripotent stem cell for neuronal differentiation induction
WO2014157257A1 (en) 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 Cell sorting method
WO2014168264A1 (en) 2013-04-12 2014-10-16 国立大学法人京都大学 Method for inducing alveolar epithelium progenitor cells
WO2014185358A1 (en) 2013-05-14 2014-11-20 国立大学法人京都大学 Efficient myocardial cell induction method
WO2014192909A1 (en) 2013-05-31 2014-12-04 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 Layered cell sheet incorporating hydrogel
WO2014200115A1 (en) 2013-06-11 2014-12-18 国立大学法人京都大学 Method for producing renal precursor cells, and drug containing renal precursor cells
WO2015020113A1 (en) 2013-08-07 2015-02-12 国立大学法人京都大学 Method for producing pancreatic hormone-producing cell
US9796962B2 (en) 2013-08-07 2017-10-24 Kyoto University Method for generating pancreatic hormone-producing cells
WO2015034012A1 (en) 2013-09-05 2015-03-12 国立大学法人京都大学 New method for inducing dopamine-producing neural precursor cells
WO2015064754A1 (en) 2013-11-01 2015-05-07 国立大学法人京都大学 Novel chondrocyte induction method
EP3929302A1 (en) 2014-07-14 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Method for identifying epitope on protein
US12241089B2 (en) 2014-07-18 2025-03-04 Kyoto University Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
US10711249B2 (en) 2014-12-26 2020-07-14 Kyoto University Method for inducing hepatocytes
EP3081638A1 (en) 2015-04-16 2016-10-19 Kyoto University Method for producing pseudo-islets
US12391921B2 (en) 2016-04-15 2025-08-19 Kyoto University Method for inducing antigen specific CD8 positive T cells
US11401504B2 (en) 2016-04-15 2022-08-02 Kyoto University Method for inducing antigen specific CD8 positive T cells
WO2017183736A1 (en) 2016-04-22 2017-10-26 国立大学法人京都大学 Method for producing dopamine-producing neural precursor cells
WO2018124118A1 (en) 2016-12-27 2018-07-05 住友化学株式会社 Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells
EP4053268A2 (en) 2017-01-20 2022-09-07 Kyoto University Method for producing cd8alpha+beta+cytotoxic t cells
WO2018135646A1 (en) 2017-01-20 2018-07-26 国立大学法人京都大学 METHOD FOR PRODUCING CD8α+β+ CYTOTOXIC T CELLS
WO2018139548A1 (en) 2017-01-26 2018-08-02 国立大学法人大阪大学 Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells
WO2018168829A1 (en) 2017-03-14 2018-09-20 国立大学法人京都大学 Method for producing helper t cells from pluripotent stem cells
WO2018216743A1 (en) 2017-05-25 2018-11-29 国立大学法人京都大学 Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell
WO2018235583A1 (en) 2017-06-19 2018-12-27 公益財団法人神戸医療産業都市推進機構 Method of predicting differentiation ability of pluripotent stem cells and reagent therefor
WO2019078263A1 (en) 2017-10-17 2019-04-25 国立大学法人京都大学 Method for obtaining artificial neuromuscular junction from pluripotent stem cells
WO2020013315A1 (en) 2018-07-13 2020-01-16 国立大学法人京都大学 METHOD FOR PRODUCING γδ T CELLS
WO2020017575A1 (en) 2018-07-19 2020-01-23 国立大学法人京都大学 Plate-shaped cartilage derived from pluripotent stem cells and method for producing plate-shaped cartilage
WO2020022261A1 (en) 2018-07-23 2020-01-30 国立大学法人京都大学 Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
WO2020116606A1 (en) 2018-12-06 2020-06-11 キリンホールディングス株式会社 Production method for t cells or nk cells, medium for culturing t cells or nk cells, method for culturing t cells or nk cells, method for maintaining undifferentiated state of undifferentiated t cells, and growth-accelerating agent for t cells or nk cells
WO2020130147A1 (en) 2018-12-21 2020-06-25 国立大学法人京都大学 Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
WO2020138371A1 (en) 2018-12-26 2020-07-02 キリンホールディングス株式会社 Modified tcr and production method therefor
WO2020230832A1 (en) 2019-05-15 2020-11-19 味の素株式会社 Method for purifying neural crest cells or corneal epithelial cells
WO2020235319A1 (en) 2019-05-20 2020-11-26 味の素株式会社 Expansion culture method for cartilage or bone precursor cells
WO2021117886A1 (en) 2019-12-12 2021-06-17 国立大学法人千葉大学 Freeze-dried preparation containing megakaryocytes and platelets
WO2021174004A1 (en) 2020-02-28 2021-09-02 Millennium Pharmaceuticals, Inc. Method for producing natural killer cells from pluripotent stem cells
WO2021256522A1 (en) 2020-06-17 2021-12-23 国立大学法人京都大学 Chimeric antigen receptor-expressing immunocompetent cells
WO2022014604A1 (en) 2020-07-13 2022-01-20 国立大学法人京都大学 Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
WO2022019152A1 (en) 2020-07-20 2022-01-27 学校法人 愛知医科大学 Composition for undifferentiated maintenance culture of pluripotent cells, medium for undifferentiated maintenance culture of pluripotent cells, maintenance culture method in undifferentiated state of pluripotent cells, and method for producing pluripotent cells
WO2022039279A1 (en) 2020-08-18 2022-02-24 国立大学法人京都大学 Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells
WO2022196714A1 (en) 2021-03-17 2022-09-22 アステラス製薬株式会社 Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein
WO2022230977A1 (en) 2021-04-30 2022-11-03 国立研究開発法人理化学研究所 Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates
WO2022255489A1 (en) 2021-06-04 2022-12-08 キリンホールディングス株式会社 Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition
WO2022259721A1 (en) 2021-06-10 2022-12-15 味の素株式会社 Method for producing mesenchymal stem cells
WO2022264033A1 (en) 2021-06-15 2022-12-22 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
WO2023286832A1 (en) 2021-07-15 2023-01-19 アステラス製薬株式会社 Pericyte-like cells expressing vascular endothelial growth factor (vegf) at high level
WO2023286834A1 (en) 2021-07-15 2023-01-19 アステラス製薬株式会社 Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level
WO2023017848A1 (en) 2021-08-11 2023-02-16 国立大学法人京都大学 Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells
WO2023085356A1 (en) 2021-11-11 2023-05-19 株式会社ヘリオス Gene-modified pluripotent stem cell, immunocompetent cell derived therefrom, method for producing said cells, and use thereof
WO2023153464A1 (en) 2022-02-09 2023-08-17 住友ファーマ株式会社 Method for assessing differentiation potential of cells in culture broth in differentiation of pluripotent stem cells into neural cells of midbrain floor plate region
WO2023210713A1 (en) 2022-04-27 2023-11-02 国立大学法人京都大学 Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration
WO2023238932A1 (en) 2022-06-10 2023-12-14 国立大学法人京都大学 Detection method and detection reagent for undifferentiated pluripotent stem cells

Also Published As

Publication number Publication date
JP2011522514A (en) 2011-08-04
WO2009126250A2 (en) 2009-10-15
EP2274424A4 (en) 2012-02-01
AU2009234424A1 (en) 2009-10-15
CN102083981A (en) 2011-06-01
EP2276834A4 (en) 2012-02-08
EP2274424A2 (en) 2011-01-19
WO2009126250A3 (en) 2010-03-18
EP2276838A2 (en) 2011-01-26
KR20110006672A (en) 2011-01-20
AU2009233845A1 (en) 2009-10-15
JP2011516076A (en) 2011-05-26
WO2009126251A3 (en) 2010-03-18
JP2011516082A (en) 2011-05-26
EP2276834A2 (en) 2011-01-26
KR20110007607A (en) 2011-01-24
WO2009126655A3 (en) 2010-01-14
CN102083968A (en) 2011-06-01
CN102083982A (en) 2011-06-01
EP2276838A4 (en) 2012-02-01
US20090253203A1 (en) 2009-10-08
AU2009234423A1 (en) 2009-10-15
KR20110019727A (en) 2011-02-28
WO2009126655A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
WO2009126251A2 (en) Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
WO2010056831A2 (en) Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
US20090275032A1 (en) Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator
Bourillot et al. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog
US8357666B2 (en) Reprogramming a cell by inducing a pluripotent gene through RNA interference
US9115345B2 (en) MicroRNA induction of pluripotential stem cells and uses thereof
US11377636B2 (en) Endogenous retrovirus transcription as a marker for primate naive pluripotent stem cells
US20120322153A1 (en) Reprogramming a cell by activation of the endogenous transcription factor network
Muth et al. The dual‐specificity phosphatase Dusp15 is regulated by Sox10 and Myrf in myelinating oligodendrocytes
Wu et al. Retinoic acid induces ubiquitination-resistant RIP140/LSD1 complex to fine-tune P ax6 gene in neuronal differentiation
Trovato et al. Histone H3. 3 lysine 9 and 27 control repressive chromatin at cryptic enhancers and bivalent promoters
Henriksen et al. Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells
Addicks Epigenetic Regulation of Muscle Stem and Progenitor Cells
Shah Human neuronal LUHMES cell line as a model system for studying Rett syndrome
Georgieva et al. Regulation of NSL by TAF4A is critical for genome stability and quiescence of muscle stem cells
Fasciani Development of an in vitro disease model for dissecting the epigenetic mechanisms underlying pathogenesis of Kabuki syndrome
Carrió Gaspar DNA Methylation Dynamics during Myogenesis
Pollina Chromatin and Transcriptional Regulation of Cell Identity and Aging
Seale Zac1, a zinc finger transcription factor, is a direct Pax7 target gene in post-natal myogenesis
Sotirova Inactivation of Ube3a in P19 embryonic carcinoma cells by RNA interference
Parente Function of Polycomb group proteins in embryonic stem cells
Brichta Molecular genetic investigations of histone deacetylase inhibitors as potential neurotherapeutics for autosomal recessive proximal spinal muscular atrophy (SMA)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980120752.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09729724

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011503981

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107024997

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009234424

Country of ref document: AU

Ref document number: 2009729724

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 7841/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009234424

Country of ref document: AU

Date of ref document: 20090407

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载